WO1998023635A1 - Novel promiscuous t helper cell epitopes - Google Patents
Novel promiscuous t helper cell epitopes Download PDFInfo
- Publication number
- WO1998023635A1 WO1998023635A1 PCT/AU1997/000820 AU9700820W WO9823635A1 WO 1998023635 A1 WO1998023635 A1 WO 1998023635A1 AU 9700820 W AU9700820 W AU 9700820W WO 9823635 A1 WO9823635 A1 WO 9823635A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- amino acid
- acid sequences
- sequences encoding
- epitope
- Prior art date
Links
- 210000002443 helper t lymphocyte Anatomy 0.000 title abstract description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 280
- 150000001413 amino acids Chemical class 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 230000028993 immune response Effects 0.000 claims abstract description 33
- 241001631646 Papillomaviridae Species 0.000 claims abstract description 24
- 230000002163 immunogen Effects 0.000 claims abstract description 21
- 238000007792 addition Methods 0.000 claims abstract description 8
- 238000012217 deletion Methods 0.000 claims abstract description 8
- 230000037430 deletion Effects 0.000 claims abstract description 8
- 238000006467 substitution reaction Methods 0.000 claims abstract description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 94
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 108091006116 chimeric peptides Proteins 0.000 claims description 46
- 108090000565 Capsid Proteins Proteins 0.000 claims description 30
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 30
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 claims description 25
- 230000003612 virological effect Effects 0.000 claims description 24
- 239000002671 adjuvant Substances 0.000 claims description 18
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 244000052769 pathogen Species 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 118
- 241000699670 Mus sp. Species 0.000 description 48
- 238000000338 in vitro Methods 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 30
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 29
- 230000009696 proliferative response Effects 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 23
- 238000011740 C57BL/6 mouse Methods 0.000 description 19
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 17
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 16
- 230000002062 proliferating effect Effects 0.000 description 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 16
- 241000701806 Human papillomavirus Species 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 239000000427 antigen Substances 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 241000701447 unidentified baculovirus Species 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 102000043131 MHC class II family Human genes 0.000 description 7
- 108091054438 MHC class II family Proteins 0.000 description 7
- 208000009608 Papillomavirus Infections Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000001516 cell proliferation assay Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 102000054766 genetic haplotypes Human genes 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 241000341655 Human papillomavirus type 16 Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 229940023041 peptide vaccine Drugs 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- 206010059313 Anogenital warts Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101150075239 L1 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000223960 Plasmodium falciparum Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- -1 9-fluorenylmethoxycarbonyl (Fmoc) Chemical class 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000000907 Condylomata Acuminata Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701828 Human papillomavirus type 11 Species 0.000 description 1
- 101000622322 Human papillomavirus type 16 Regulatory protein E2 Proteins 0.000 description 1
- 241000709701 Human poliovirus 1 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 108010048188 MS2 polymerase Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001644525 Nastus productus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000283222 Physeter catodon Species 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
- 201000004201 anogenital venereal wart Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010218 electron microscopic analysis Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 108010071296 lipid-associating peptides Proteins 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000000263 nonmitogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108700010945 porcine parvovirus VP2 Proteins 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- TITLE "NOVEL PROMISCUOUS T HELPER CELL EPITOPES" FIELD OF INVENTION
- This invention relates to promiscuous T helper cell epitopes, and in particular, novel promiscuous T helper cell epitopes which have utility in the development of novel peptide-based vaccines.
- the invention also extends to vaccine compositions which include the novel promiscuous epitopes of the invention which may be useful in eliciting an immune response against PV and particularly HPV (human papillomavirus) in a host animal.
- HPV human papillomavirus
- Papillomaviruses induce benign hyperproliferative lesions in humans and in many animal species, some of which undergo malignant conversion.
- the biology of papillomavirus infection is summarised in a review by J. P. Sundberg entitled “Papillomavirus Infections in Animals” In “Papillomaviruses and Human Disease” edited by K. Syrjanen, L. Gissmann and L. G. Koss, Springer Verlag (1987).
- Papillomaviruses are a family of small DNA viruses encoding up to eight early (E1 , E2, E3, E4, E5, E6, E7 and E8) and two late genes (L1 and L2). These viruses have been classified in several distinct groups such as HPV which are differentiated into types 1 to 70 depending upon DNA sequence homology. A clinicopathological grouping of HPV and the malignant potential of the lesions with which they are most frequently associated are summarised in "Papillomaviruses and Human Cancer" by H. Pfister, CRC Press, Inc. (1990).
- HPV type 1 (HPV-1 ) is present in plantar warts
- HPV-6 or HPV-11 are associated with condylomata acuminata (anogenital warts)
- HPV-16 or HPV-18 are common in pre- malignant and malignant lesions of the cervical squamous epithelium.
- HPV-16 E6 Stacey et al., 1992, J. Gen. Virol. 73 2337; Bleul et al., 1991 , J. Clin. Microbiol. 29 1579; Dillner, 1990, Int. J. Cancer 46 703; and M ⁇ ller e. a/., 1992, Virology 187 508
- HPV-16 E2 Dillner et al., 1989, Proc. Natl. Acad. Sci. USA 863838; Dillner, 1990, supra; Lehtinen et al., 1992, J. Med. Virol.
- Peptides can be synthesised in large quantities with high purity and are chemically well defined. Synthetic peptides can be designed to incorporate any antigenic B and T epitope (Tindle et al., 1991 , Proc. Natl. Acad. Sci. USA 88 5887-5891 ), and exclude potentially deleterious or dangerous functional domains of a protein (Berzofsky, J. A., 1991 , FASEB J. 5 2412-2418).
- uncoupled, carrier free peptide or peptides must contain domains which activate T-helper (Th) cells as well as B-cells so as to facilitate their cognate interaction leading to the development of an effective immune response (Mitchinson, 1971 , Eur. J. Immunol. 1 10-17; Mitchinson, 1971 , Eur. J. Immunol. 1 18-24; Abbas et al., 1985, J. Immunol. 135 1661-1667).
- cytotoxic T lymphocyte CTL activation which activation is important for effective immune control of tumours and viral infections.
- CTL cytotoxic T lymphocyte
- recent experiments have shown that induction of antigen-specific CTL can be effected by linking a Th- cell epitope directly or indirectly to a CTL epitope.
- Th-cell determinants The identification of defined Th-cell determinants and their use to provide effective carrier help to short constructs representing a B-cell epitope or CTL epitope have made it possible to synthesize putative immunogens.
- the use of Th-cell epitopes in the development of potentially immunogenic chimeric constructs has generally been restricted because of the propensity of Th-cells only to provide 'help' to B-cells and/or CTLs displaying the same processed MHC-restricted form of the antigen.
- the inclusion of Th-cell epitopes in chimeric constructs comprising B-cell and/or CTL determinants is genetically restricted to only one or a few alleles of the MHC with limited activity across divergent MHC class II haplotypes.
- Th-cell epitopes which can be recognized in the context of several MHC (as well as HLA) haplotypes have been identified in a number of proteins.
- Partidos et al. (1991 , J. Gen. Virol. 72 1293-1299) have identified a Th-cell epitope from the fusion protein (F) of measles virus which is immunogenic in a panel of mouse strains of different H-2 types and in seven of 10 humans tested.
- F fusion protein
- Copolymer 1 a synthetic basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis (EAE)
- EAE experimental allergic encephalomyelitis
- Th-cell epitopes derived from tetanus toxin, sperm-whale myoglobin and streptococcal protein have been found capable of imparting help to B-cell determinants taken, respectively, from the human malarial parasite Plasmodium falciparum (Etlinger ef a/., 1990, Science, 249 423-425; Kumar et al., 1992, J. Immunol. 148 1499-1505), foot-and-mouth disease virus (Francis et al., 1987, Nature 300 168-170) and hepatitis B virus (LeClerc et al., 1987, Eur. J. Immunol. 17 269-273).
- DRAHYNI the promiscuous Th-cell minimal proliferative epitope
- HPV human papillomavirus
- Th-cell epitopes In view of the plethora of Th-cell epitopes defined in the literature which epitopes have been derived from a myriad of different organisms, only a few have been shown to be reactive on several MHC backgrounds (Kaumaya et al., 1993, J. Mol. Recognit. 6 81-94; Domanico et al., 1993, Eur. J. Immunol. 23 1011-1016; Reece et al., 1994, J. Immunol. Methods 171 241-254).
- the current invention arises from the unexpected discovery that peptide sequences within HPV-16 E6, which have substantially different structures to the DRAHYNI epitope of HPV-16 E7, are reactive on several
- HPV-16 E6 peptides when combined with different B-cell epitopes in chimeric peptide constructs elicit specific antibodies which react with peptides containing the B-cell epitopes.
- T-cell epitopes which chimeric peptides may be utilized to generate immune responses against the B-cell epitope(s) and/or the cytotoxic T-cell epitope(s).
- a peptide encoding a promiscuous T helper cell epitope for generating an immune response against papillomavirus, said peptide selected from the group consisting of:-
- VYRDGNPYA inclusive of a single amino acid deletion, substitution or addition made therein
- QYNKPLCDLL inclusive of a single amino acid deletion, substitution or addition made therein
- the invention also contemplates 'peptide homologs' of peptides according to SEQ ID NO 1 and SEQ ID NO 2.
- the invention also includes within its scope peptides which are functionally similar to those defined in SEQ ID NO 1 and SEQ ID NO 2.
- conservative amino acid substitutions can be made in peptides according to SEQ ID NO 1 and SEQ ID NO 2 (parent peptides) and that such substituted peptides will retain the functional characteristics of the parent peptides.
- the peptides of the invention may be prepared using any suitable procedure. Preferably, such peptides are synthesized either manually or by using an automated peptide synthesiser.
- Peptides according to SEQ ID NO 1 and SEQ ID NO 2 and peptide homologs thereof may be synthesised using solution synthesis or solid phase synthesis as described, for example, in Chapter 9 entitled “Peptide Synthesis” by Atherton and Shephard which is included in a publication entitled “Synthetic Vaccines” edited by Nicholson and published by Blackwell Scientific Publications.
- a peptide in accordance with the invention may be prepared by a procedure including the steps of: (a) ligating a nucleotide sequence encoding a peptide according to SEQ ID NO 1 , SEQ ID NO 2 or peptide homolog thereof into a suitable expression vector to form an expression construct;
- an expression construct is a nucleotide sequence comprising a first nucleotide sequence encoding a peptide according to SEQ ID NO 1 , SEQ ID NO 2 or peptide homolog thereof wherein said first sequence is operably linked to regulatory nucleotide sequences (such as a promoter and a termination sequence) that will facilitate expression of said first sequence. Both constitutive and inducible promoters may be useful adjuncts for expression of the peptides according to the invention.
- the expression construct preferably includes a vector, such as a plasmid cloning vector.
- a vector according the invention may be a prokaryotic or a eukaryotic expression vector, which are well known to those of skill in the art.
- Suitable host cells for expression may be prokaryotic or eukaryotic.
- One preferred host cell for expression of a peptide according to the invention is a bacterium.
- the bacterium used may be Escherichia coli.
- the recombinant peptide may be conveniently prepared by a person skilled in the art using standard protocols as for example described in Sambrook et al. (1989, second edition, Cold Spring Harbor Laboratory Press, in particular Sections 16 and 17).
- nucleotide sequence designates mRNA, RNA, cRNA, cDNA or DNA.
- a nucleotide sequence encoding the peptides of the invention may be conveniently prepared by taking advantage of the genetic code and synthesising, for example, by use of an oligonucleotide sequencer, a sequence of nucleotides which when translated by a host cell results in the production of a peptide according to SEQ ID NO 1 , SEQ ID NO 2 or peptide homolog thereof.
- each of the peptides according to SEQ ID NO 1 and SEQ ID NO 2 comprises minimal T helper cell proliferative sequences which are considered to incorporate the key “anchor" amino acid residues required for binding an MHC class II molecule.
- peptides associated with MHC class II molecules may comprise 10 to 34 amino acid residues, and the optimal length of a T helper cell epitope has been defined crystallographically and otherwise to be between 13 and 20 amino acids (Appella et al., 1995, EXS. 73 105-119 which is hereby incorporated by reference).
- the invention contemplates a peptide of 10 to 34 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the amino acid sequence defined by SEQ ID NO 1 or peptide homolog thereof and/or the amino acid sequence defined by SEQ ID NO 2 or peptide homolog thereof.
- the invention provides a peptide of 13 to 20 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the amino acid sequence defined by SEQ ID NO 1 or peptide homolog thereof and/or the amino acid sequence defined by SEQ ID NO 2 or peptide homolog thereof.
- a chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide in accordance with SEQ ID NO 1 or peptide homolog thereof linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
- a chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide in accordance with SEQ ID NO 2 or peptide homolog thereof linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
- the chimeric peptide construct comprises between 10 and 34 amino acids. More preferably, the chimeric peptide construct comprises between 10 and 20 amino acids.
- B-cell epitopes may be selected from any suitable source including but not necessarily limited to pathogenic organisms such as pathogenic viruses.
- a suitable pathogenic virus which may be used as a source of B-cell epitopes includes papillomavirus.
- the B-cell epitopes may comprise HPV16 E7 B-cell epitopes which include QAEPD, IDGP, EYMLD and YMLD.
- suitable B-cell epitopes that may be selected from HPV 18 E7 epitopes include DEIDGVNHQL and SEENED.
- CTL epitopes are preferably selected from a tumor or viral source.
- the virus may be a papillomavirus.
- the CTL epitope may be selected from human CTL epitopes in HPV16
- the CTL epitope may comprise a measles protein CTL epitope as described in an article by Hsu et al. (1996, Vaccine 14 1159-1166 which is hereby incorporated by reference) or an Adenovirus CTL epitope as described by Toes et al. (1996,
- X denotes a promiscuous T helper cell epitope comprising peptides selected from SEQ
- N1 , N4 and N5 represent B-cell epitope or CTL epitope sequences that may be linked to said promiscuous epitope sequences indirectly through intervening sequences of amino acids that are not B-cell or CTL epitope sequences such as A1 and A2.
- the B-cell or CTL epitope sequence may be linked directly to the promiscuous T helper epitope sequence and in such a case in a first situation the terminal amino acid of the B-cell or CTL epitope sequence and the first amino acid of said promiscuous epitope sequence may be merged. In other cases, in a second situation the last amino acid of the promiscuous T helper epitope sequence and the first amino acid of the B-cell or CTL epitope sequence may also be merged.
- N2 represents a B-cell or CTL epitope sequence which refers to the first situation and N3 represents a B-cell or CTL epitope sequence that represents the second situation.
- SEQ ID NO 1 and SEQ ID NO 2 have been identified as corresponding to two major T helper cell epitopes in the E6 open reading frame (ORF) of HPV16.
- ORF open reading frame
- Peptides according to SEQ ID NO 1 and SEQ ID NO 2 are each capable of eliciting strong antibody responses to HPV16 E6 challenge across a wide range of MHC class II backgrounds.
- chimeric constructs in accordance with the present invention comprising peptides according to SEQ ID NO 1 and SEQ ID NO 2 may facilitate the production of antibody to several B-cell epitopes simultaneously as well as several CTL epitopes simultaneously.
- the invention also includes within its scope an immunogenic composition comprising one or more of the abovementioned peptides and a suitable adjuvant or delivery vehicle.
- Suitable adjuvants may be selected from Freunds Complete Adjuvant, Freunds Incomplete Adjuvant, QuilA and saponins generally.
- the adjuvant is capable of eliciting CD8 + MHC class I restricted cytotoxic T lymphocytes.
- Suitable delivery vehicles in which the peptides of the invention may be delivered into a host animal include, but are not necessarily limited to, liposomes, membranous vehicles and microspheres which are well known to those skilled in the art.
- the delivery vehicle may be an immunostimulating complex (ISCOM).
- ISCOM immunostimulating complex
- Suitable methods for incorporation of peptides into ISCOMs include coupling peptides to influenza virus envelope glycoproteins which have already been incorporated into ISCOMs (Lovgren et al., 1987, supra; Lovgren and Larsson, supra), or coupling cysteine- containing peptides to preformed influenza ISCOMs using a heterobifunctional reagent (Larsson et al., 1993, J. Immunol.
- peptides may be incorporated into ISCOMs by copolymerisation with the lipid binding peptide LAP20 (Fernando et al., 1994, In “Vaccines 94", pp 327-331 , Cold Spring Harbour Laboratory Press).
- a preferred delivery vehicle contemplated by the invention is a chimeric VLP including a modified viral capsid protein having one or more peptides of the invention fused thereto.
- the chimeric VLP may comprise the modified viral capsid protein alone.
- the chimeric VLP may comprise the modified viral capsid protein in association with one or more other viral capsid proteins which may be required for assembly of the chimeric VLP.
- the modified viral capsid protein may be prepared from any parent viral capsid protein, including a natural viral capsid protein, which when fused with the one or more peptides results in a modified viral capsid protein which is capable of incorporating into a chimeric VLP.
- the parent viral capsid protein includes, but is not limited to, a papillomavirus capsid protein or a parvovirus capsid protein. Accordingly, the parent viral capsid protein may comprise an L1 protein or an L2 protein of a papillomavirus. In the case of parvovirus, the parent viral capsid protein may comprise a VP2 capsid protein.
- foreign peptides can be incorporated into a viral capsid protein to produce chimeric VLPs which can be used to present foreign antigens to an immune system. Suitable methodologies for production of such chimeric VLPs are also known.
- the peptides of the invention may be fused to a papillomavirus 1 L1 capsid protein as described, for example, in Muller et al (1997, Virology 23493-111 ), or fused to a papillomavirus L2 capsid protein as described, for example, in United States Patent No 5,618,536 (Lowy et al) which is hereby incorporated by reference, or fused to a porcine parvovirus VP2 capsid protein as described, for example, in Sedlik et al (1997, Proc. Natl. Acad. Sci. USA 94 7503-7508) which is hereby incorporated by reference.
- the above exemplary methods of producing chimeric VLPs essentially involve construction of a synthetic DNA molecule encoding the modified viral capsid protein and subsequent expression of this protein in a suitable host cell to facilitate assembly of the chimeric VLP.
- a suitable host cell to facilitate assembly of the chimeric VLP.
- such expression may require co-expression of one or more other viral capsid proteins for assembly of the chimeric VLP.
- the synthetic DNA molecule may be prepared using any suitable method for altering DNA. Such methods are well known to those of skill in the art and are described for example in the relevant sections of CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel, et al., eds.) (John Wiley & Sons, Inc. 1995) and of Sambrook, et al., MOLECULAR CLONING. A LABORATORY MANUAL (Cold Spring Harbor Press, 1989) which are hereby incorporated by reference. Alternatively, suitable methods for altering DNA are set forth, for example, in U.S. Patent Nos 4,184,917, 4,321 ,365 and 4,351 ,901 which are hereby incorporated by reference.
- the synthetic DNA molecule may be ligated into a suitable expression vector to produce a recombinant expression vector may be introduced subsequently into a host cell for expression of the modified viral capsid protein.
- the expression vector is a baculovirus expression vector and the host cell is a Spodoptera frugiperda 9 (Sf-9) insect cell.
- FIG. 1 refers to a set of overlapping peptides (termed GF51- GF66) spanning the putative HPV16 E6 protein molecule;
- FIG.2 illustrates the overlapping pattern of the peptides of FIG.
- FIG. 3A is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized subcutaneously with saline: CFA, and challenged with individual HPV16 E6 peptides
- FIG. 3B is a bar graph showing the in vitro proliferative repsonse of LNCs from H-2 b mice immunized subcutaneously with saline: CFA, and challenged with PPD + individual HPV16 E6 peptides;
- FIG. 4A is a bar graph showing the in vitro proliferative response of LNCs from H-2 mice immunized with peptides GF51-GF54;
- FIG. 4B is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized with peptides GF55-GF58;
- FIG. 4C is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized with peptides GF59-GF62;
- FIG. 4D is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized with peptides GF63-GF66;
- FIG. 5A illustrates the in vitro proliferative response of LNCs from H-2 mice immunized subcutaneously with an equimolar mixture of peptide GF56;
- FIG. 5B is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized subcutaneously with an equimolar mixture of peptide GF57;
- FIG. 5C is a bar graph showing the in vitro proliferative response of LNCs from H-2 mice immunized subcutaneously with an equimolar mixture of peptide GF61 ;
- FIG. 5D is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized subcutaneously with an equimolar mixture of peptide GF66;
- FIG. 5E is a bar graph showing the in vitro proliferative response of LNCs from H-2 b mice immunized subcutaneously with an equimolar mixture of peptide GF51 ;
- FIG. 6A is a bar graph showing the T-proliferative response of
- FIG. 6B is a bar graph showing the T-proliferative response of LNCs from B10 (H-2 a ) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
- FIG. 6C is a bar graph showing the T-proliferative response of LNCs from B10 (H-2 k ) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
- FIG. 6D is a bar graph showing the T-proliferative response of LNCs from B10 (H-2 d ) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
- FIG. 6E is a bar graph showing the T-proliferative response of
- FIG. 6F is a bar graph showing the T-proliferative response of LNCs from B10 (H-2 h4 ) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
- FIG. 7 illustrates the mapping of the minimal T-cell proliferative epitope in the GF57 peptide of HPV16E6 protein
- FIG. 8A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF57, and challenged with 20 ⁇ g/mL GF57 overlapping truncated peptides;
- FIG. 8B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF57, and challenged with 5 ⁇ g/mL GF57 overlapping truncated peptides;
- FIG. 9 illustrates the mapping of the minimal T-cell proliferative epitope in the GF61 peptide of HPV16E6 protein
- FIG. 10A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF61 , and challenged with 20 ⁇ g/mL GF57 overlapping truncated peptides;
- FIG. 10B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF61 , and challenged with 5 ⁇ g/mL GF57 overlapping truncated peptides;
- FIG. 11A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 20 ⁇ g/mL GF57 overlapping truncated peptides;
- FIG. 11 B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 5 ⁇ g/mL GF57 overlapping truncated peptides
- FIG. 12A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 20 ⁇ g/mL GF61 overlapping truncated peptides;
- FIG. 12B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 5 ⁇ g/mL GF61 overlapping truncated peptides;
- FIG. 13A is a bar graph showing the effect of 'VYRDGNPYA' T h -epitope on the antibody response to ⁇ YMLD' B-epitope;
- FIG. 13B is a bar graph showing the effect of 'QYNKPLCDLL'
- FIG. 13C is a bar graph showing the effect of 'VYRDGNPYA' T h -epitope on the antibody response to 'QAEPD' B-epitope;
- FIG. 13D is a bar graph showing the effect of 'QYNKPLCDLL' T h -epitope on the antibody response to 'QAEPD' B-epitope.
- FIG. 14 is a map of recombinant vector pVLBPVI L1/Thprom- QAEPD.
- buffers Unless otherwise specified, buffers were prepared according to Sambrook et al. (1989, MOLECULAR CLONING. A LABORATORY
- HPV16 E6 and HPV16 E7 proteins were produced as MS2- fusion proteins from a heat-inducible phage promoter in a pPLc24 expression vector (provided by L. Gissmann, DKFZ, Heidelberg, Germany) in E. coli C600/537 by sequential urea extraction, as described by Seedorf et al. 1987.
- the expression vector pPLc24 allows the expression of inserts fused to the N-terminal part (the first 98 aas) of the MS2 polymerase under the control of the lambda P L promoter which does not contain the cl gene coding for repressor (Remaut et al., 1981 , Gene 15 81-93; Remaut et al., 1983, Gene 22 103-113; Remaut et al., 1983, Nucleic Acids Res. 11 4677- 4688). But since the E.
- coli C600/537 strain harbors a temperature-sensitive cl repressor gene of phage lambda on a multicopy plasmid conferring kanamycin resistance
- expression of the pPLc24 vector was induced in log phase cells by incubating at 42°C for 3 hrs. After induction, cells of a 1 L LB broth culture were first washed with Bacterial Wash Buffer, then lysed in 40 imL Bacterial Lysis Buffer in the presence of 8 mg lysozyme and incubated, with shaking, at 37°C for 30 min. Next, MS2-replicase fusion proteins were partly purified by the addition of 0.1% Triton X-100.
- the final pellet was also stored at -70 O for further testing.
- SDS-PAGE Western Blotting and estimating the percentage of purity of the 7M Urea supernatant, the latter was dialyzed against PBS at 4°C, using a 12,000 mwt cut off membrane.
- the other gel was transferred by Western Blotting onto a nitrocellulose membrane using SDS Transfer Buffer at a 100 V according to standard procedures.
- the blot was blocked with 5% skim milk powder in PBS Blocking Buffer (PBS/milk) at 4°C o/n.
- PBS Blocking Buffer PBS/milk
- the second day it was incubated at RT for 1-1.5 hr with a rabbit polyclonal anti HPV16 E6/MS2 antiserum (previously prepared in our laboratory) diluted 1 :200 in PBS/milk. This was followed by 3 washes (each for 10 min) with the following Wash Buffer: 5% skim milk powder in PBS + 0.1% Triton X-100.
- Reagent A Basic reagent
- BCA bicinchoninic acid
- sample or bovine serum albumin, BSA, standard or blank
- Working Reagent 50 parts Reagent A + 1 part Reagent B
- absorbance at 540 nm was determined by spectrophotometry using a Titertek Multiskan reader.
- the protein concentration was estimated by comparison of the mean OD540 (mean of 3 wells) obtained with the sample, with that obtained with the BSA standards.
- inbred mouse strains were obtained from the Animal Resources Centre (Perth, Australia) and were used at 7-10 weeks of age.
- inbred Balb/c mice these were obtained from the same source and were used at 4-12 weeks of age.
- Overlapping synthetic peptides covering the entire HPV16 E6 ORF were used as antigens. These peptides were synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry on an Applied Biosystems 431 A peptide synthesizer. After obtaining the 'peptide- resin' conjugates, the actual peptide was next cleaved from its resin by the addition of thioanisole and ethanedithiol, and then ether purified.
- Fmoc 9-fluorenylmethoxycarbonyl
- HPV16 E6 protein was produced as an MS2 fusion protein as described above. Fusion protein was then dialyzed against PBS for use in proliferation assays.
- Lymph Node Cell LNC Proliferation Assays Mice were immunized subcutaneously in the base of the tail with about 50 ⁇ g of peptide emulsified in Complete Freund's Adjuvant (H37 Ra. CFA, Difco).
- DMEM Dulbecco's Modification of Eagle's Medium
- the LNCs suspension was prepared at a concentration of 2x10 6 cells per mL in cDMEM containing 10% FCS.
- a four day proliferation assay (at 37°C) (Good et al. , 1987, Science 235 1059-1062) was conducted in peptide-coated microtiter plates where every peptide-coated well was allowed to interact with 4x10 5 LNCs/mL (200 ⁇ L of LNCs suspension).
- Wells coated with Purified Protein Derivative (PPD) or cDMEM were used as positive and negative controls, respectively.
- LNCs lymph-node cells
- PPD purified protein derivative
- mice were immunized with equimolar mixes of peptides GF51 - GF54, GF55 - GF58, GF59 - GF62 or GF63 - GF66 respectively in CFA. Pooled LNCs from each group were challenged in vitro with individual peptides at 2 or 20 ⁇ g/mL.
- Peptide GF57 elicited strong proliferation and GF56 weaker proliferation in LNCs from the GF55 - GF58 immunized group (FIGS.4A, 4B, 4C and 4D). Moreover, a proliferative response was elicited with peptide GF61 in LNCs from the GF59 - GF62 immunized group (FIGS. 4A, 4B, 4C and 4D). No further peptides from GF51 - GF66 series induced proliferation in assays using LNCs from appropriately immunized H-2 b mice.
- C57BL/6 mice were then immunized with mixtures of peptides GF56, GF57, GF61 and irrelevant peptide GF66 in CFA.
- LNCs from these mice were challenged in vitro with individual peptides at different concentrations (20 ⁇ g/mL, 10 ⁇ g/mL, 5 ⁇ g/mL, 2.5 ⁇ g/mL, 1.25 ⁇ g/mL and 0.63 ⁇ g/mL).
- 5A, 5B, 5C, 5D and 5E shows that the LNCs response to peptides GF56, GF57 and GF61 decreased with decreasing concentration of the challenging peptide and that the minimal dose of challenging peptide which would still elicit good proliferation is 5 ⁇ g/mL. No response to challenging control peptides GF66 or GF51 was noticed.
- peptides GF56, GF57 and GF61 each contains a T-proliferative epitope(s) reactive in H-2 b mice; while peptide GF56 contains a "promiscuous" T-epitope, reactive on several murine MHC backgrounds.
- LNCs from GF57 immunized mice were challenged in vitro with a series of overlapping peptides, truncated by 1 amino acid from either the N-terminal or the C-terminal, and covering the whole length of peptide GF57 (FIG. 7) at different concentrations (20 ⁇ g/mL, 5 ⁇ g/mL, 2 ⁇ g/mL and 0.5 ⁇ g/mL).
- LNCs did not proliferate when challenged with peptides GF61 /17-18, probably because of the Leucine and Isoleucine being two hydrophobic residues at the C- terminal end of the peptide molecule competing to fit into the T-cell receptor groove on the antigen presenting cell (APC) and resulting in an unstable peptide molecule.
- H-2 b mice were immunized three times at two weekly intervals with a subunit vaccine consisting of synthetic peptides containing either VYRDGNPYA or QYNKPLCDLL T-epitope linked to known HPV16 E7 B-cell epitopes (Tindle et al, 1990, J. Gen. Virol. 71 1347-1354):
- the defined proliferative T-epitopes in HPV16 E6 are actually functional T-helper epitopes that can be used for eliciting cognate interaction between T- and B-lymphocytes for the production of antibody against the B-cell epitopes.
- the , 51 DFAFRDLCIVYRDGNPYA 68 ' peptide GF56 was shown to contain a promiscuous T-proliferative epitope, reactive on several MHC backgrounds.
- T-epitope immunodominance depends on several mechanisms such as antigen processing, competition for binding to MHC, hindering structures outside the minimal epitopes and structures of the T-cell site (Partidos and Steward, 1992, J. Gen. Virol. 73 1987-1994; Boehncke et al., 1993, ; Grewal et al., 1995; Moudgil et al., 1996).
- GF56 contains a T-epitope other than 'VYRDGNPYA', which is proliferative on several MHC haplotypes.
- 'QYNKPLCDLL' are located adjacently to 'Cys-X-X-Cys' motifs, 'VYRDGNPYA' being localised to the first loop formed by the four 'Cys-X-X- Cys' motifs present in HPV16 E6 and 'QYNKPLCDLL' present in the region between the loops. It is believed that these motifs play an important role in the function of the E6 protein. They are involved in metal binding and have been shown to be involved in transcriptional regulation (Lamberti et al., 1990, EMBO J. 9 1907-1913) and contribute to E6-mediated transformation by binding to p53 and enhancing its degradation.
- 'VYRDGNPYA' and 'QYNKPLCDLL' are capable of eliciting cognate interaction between T- and B-lymphocytes and therefore may be used generically to produce a subunit synthetic peptide vaccine consisting of a promiscuous T helper cell epitope according to the invention, in combination with one or more B-cell epitopes and/or one or more CTL epitopes, to generate immune responses against the B-cell and/or CTL epitopes.
- the defined promiscuous T-helper epitopes in HPV16 E6 protein are reactive with a plurality of different MHC class II haplotypes and thus may be used in a vaccine construct to treat HPV infections by providing immunity to HPV infection across a broad spectrum of MHC backgrounds.
- baculovirus transfer vector Primers 5'-CCGCAATCCATGGCGTTGTGGCAACAAGGCC- AGAAGC-3' and 5'-CCGGAATTCTTATTTTTTATCAGGTTCAGCTT- GAGCATAAGGATTGCCATCCCGATAAACTCCTGCCCCTTGCTGTGCT AAAAATCTTCTTCC-3' may be utilized to allow amplification by PCR of a hybrid nucleotide sequence encoding a modified BPV1 L1 gene in which a chimeric peptide comprising the minimal promiscuous epitope VYRDGNPYA and the HPV16 E7 B-cell epitope QAEPD, is fused to the C-terminus of the BPV1 L1 sequence.
- This fusion would result in deletion of nucleotides from 7625 downstream of the BPV1 nucleotide sequence.
- the above primers would also facilitate insertion of a stop codon, and one flanking BamYW site at the 5' end and a flanking ⁇ coRI site at the 3' end of the hybrid nucleotide sequence.
- the PCR products could be digested with SamHI and EcoRI and inserted subsequently into the baculovirus transfer vector pVL1393 (Pharmingen) at the BamYW and EcoRI sites thereof before transformation of DH-5 ⁇ cells. Recombinant clones having the correct sequence could be confirmed by restriction endonuclease and nucleotide sequence analyses.
- a map of a recombinant baculovirus transfer vector pVLBPV1 L1/Thprom-QAEPD so produced is shown in FIG. 14.
- Recombinant baculoviruses could be produced according to Pharmingen's BaculoGoldTM transfection kit. Briefly, Spodoptera frugiperda 9 (Sf-9) insect cells are co-transfected with BaculoGoldTM linearized DNA and the recombinant transfer vectors. Preferably, plaque purification is used to ensure no non-recombinant (wild-type) plaques are detected. High-titer (> 10 8 /mL virus particles) stocks of recombinant baculoviruses are obtained subsequently by two rounds of amplification.
- Spodoptera frugiperda 9 (Sf-9) insect cells are co-transfected with BaculoGoldTM linearized DNA and the recombinant transfer vectors.
- plaque purification is used to ensure no non-recombinant (wild-type) plaques are detected.
- High-titer (> 10 8 /mL virus particles) stocks of recombinant baculoviruses are obtained subsequently
- the cell suspension is then homogenized with a dounce homogenizer (tight pestle) by 50 strokes on ice and then centrifuged at 3000 rpm for 10 min at 4°C to separate the nuclear fraction.
- the nuclear pellet is then resuspended in an appropriate resuspension buffer and sonicated for 45 sec on ice.
- the nuclear suspension is then loaded onto a 20% sucrose cushion and centrifuged at 26,000 rpm in a Beckman SW-26 rotor at 4°C for 2 h. The pellets are then resuspended in resuspension buffer and sonicated again for another 45 sec.
- the resulting sonicate is then mixed with CsCI and centrifuged at 21 °C in a Beckman SW 41 rotor for 20 H.
- a band at the CsCI density of about 1.30 g/mL is then collected and dialysed against PBS.
- the sample may then be used for Western immunoblotting and for transmission electron microscopic analysis for confirming respectively the integrity of the modified BPV1 L1 capsid protein and chimeric VLP structure.
- FIG. 1 A set of overlapping peptides (termed GF51-GF66) spanning the putative HPV16 E6 protein molecule. These peptides were synthesized by Fmoc chemistry. Peptides are shown using the single letter code. The numbers of the first and last amino acids of each peptide correspond to amino acid numbers of the HPV16 E6 polypeptide sequence.
- FIG. 2 Overlapping pattern of the peptides of FIG. 1 relative to the amino acid sequence of HPV16 E6 protein.
- the first and last amino acid (single letter code) indicated for each peptide correspond to the amino acid numbering of HPV16 E6 protein.
- FIGS. 3A and 3B Mitogenicity and toxicity assays of the HPV16 E6 overlapping peptides. Each recall peptide was used at two different concentrations: 20 ⁇ g/mL (hatched bars), and 2 ⁇ g/mL (dotted bars). "NIL" represents background (no added antigen).
- FIGS. 4A - 4D LNC proliferation assays. Each recall peptide was used at two different concentrations: 20 ⁇ g/mL (hatched bars), and 2 ⁇ g/mL (dotted bars). "NIL” represents background (no added antigen). Irrelevant peptides GF55 (FIG. 4A), GF59 (FIG. 4B), GF63 (FIG. 4C) and GF51 (FIG. 4D) were used as negative controls in their respective groups.
- FIGS. 5A - 5E In vitro proliferative response of LNCs from H-2 b mice immunized subcutaneously with an equimolar mixture of peptide GF56 FIG. 5A), GF57 (FIG. 5B), GF61 (FIG. 5C), GF66 (FIG. 5D) and GF51 (FIG. 5E). Recall peptide GF51 was used as a negative control. Mean proliferation with PPD positive control was 122.0541 x 10 3 cpm. "NIL" represents background (no added antigen).
- FIGS. 6A - 6F In vitro proliferative response of LNCs from H-2 b mice immunized subcutaneously with an equimolar mixture of peptide GF56 FIG. 5A), GF57 (FIG. 5B), GF61 (FIG. 5C), GF66 (FIG. 5D) and GF51 (FIG. 5E). Recall peptide GF51 was used as
- FIG. 7 Mapping of the minimal T-cell proliferative epitope in the GF57 peptide of HPV16E6 protein. Underlined amino acids indicate the minimal T-cell proliferative epitope.
- FIGS. 8A and 8B In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF57, and challenged with GF57 overlapping truncated peptides. Recall peptides GF57 and GF51 were used as positive and negative controls respectively. "NIL" represents background (no added antigen).
- FIG. 9 Mapping of the minimal T-cell proliferative epitope in the GF61 peptide of HPV16E6 protein. Underlined amino acids indicate the minimal T-cell proliferative epitope.
- FIGS. 10A and 10B In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF61 , and challenged with GF57 overlapping truncated peptides. Recall peptides GF61 and GF51 were used as positive and negative controls respectively. "NIL" represents background (no added antigen).
- FIGS. 11A and 11B In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with GF57 overlapping truncated peptides. "NIL” represents background (no added antigen).
- FIGS. 12A and 12B In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with GF61 overlapping truncated peptides. "NIL” represents background (no added antigen).
- FIGS. 13A - 13D Effect of 'VYRDGNPYA' and 'QYNKPLCDLL' T h -epitopes on the antibody response to 'EYMLD' and 'QAEPD' B-epitopes.
- Peptide GF101 MHGDTPTLHEYMLDLQPE
- 8Q QAEPDRAHYNIVTFCCKCD
- 8F and 6D are MAbs to EYMLD and QAEPD respectively.
- Sera were collected from H-2 b mice before and after immunization with either VYRDGNPYA (VYR) alone, QYNKPLCDLL (QYN) alone, VYRDGNPYA linked to EYMLD and QAEPD (E-VYR-Q), QYNKPLCDLL linked to EYMLD and QAEPD (E-QYN-Q) or with a peptide consisting of EYMLD and QAEPD epitopes only (E-Q).
- FIG. 14 Construction of recombinant baculovirus transfer vector pVLBPV1 L1/Thprom-QAEPD.
Abstract
The invention is directed to a peptide encoding a promiscuous T helper cell epitope for generating an immune response against papillomavirus, wherein the peptide is selected from the group consisting of (i) VYRDGNPYA inclusive of a single amino acid deletion, substitution or addition made therein (SEQ ID NO. 1); and (ii) QYNKPLCDLL inclusive of a single amino acid deletion, substitution or addition made therein (SEQ ID NO. 2). The invention is also concerned with chimeric constructs as well as immunogenic compositions comprising the peptides of the invention.
Description
TITLE "NOVEL PROMISCUOUS T HELPER CELL EPITOPES" FIELD OF INVENTION This invention relates to promiscuous T helper cell epitopes, and in particular, novel promiscuous T helper cell epitopes which have utility in the development of novel peptide-based vaccines. The invention also extends to vaccine compositions which include the novel promiscuous epitopes of the invention which may be useful in eliciting an immune response against PV and particularly HPV (human papillomavirus) in a host animal.
BACKGROUND OF THE INVENTION Papillomaviruses induce benign hyperproliferative lesions in humans and in many animal species, some of which undergo malignant conversion. The biology of papillomavirus infection is summarised in a review by J. P. Sundberg entitled "Papillomavirus Infections in Animals" In "Papillomaviruses and Human Disease" edited by K. Syrjanen, L. Gissmann and L. G. Koss, Springer Verlag (1987).
Papillomaviruses are a family of small DNA viruses encoding up to eight early (E1 , E2, E3, E4, E5, E6, E7 and E8) and two late genes (L1 and L2). These viruses have been classified in several distinct groups such as HPV which are differentiated into types 1 to 70 depending upon DNA sequence homology. A clinicopathological grouping of HPV and the malignant potential of the lesions with which they are most frequently associated are summarised in "Papillomaviruses and Human Cancer" by H. Pfister, CRC Press, Inc. (1990). For example, HPV type 1 (HPV-1 ) is present in plantar warts, HPV-6 or HPV-11 are associated with condylomata acuminata (anogenital warts), and HPV-16 or HPV-18 are common in pre- malignant and malignant lesions of the cervical squamous epithelium.
The immunological approach to the prevention of HPV disease requires a thorough analysis of the viral proteins against which humoral and cellular immune responses are mounted during and after infection. However,
despite recent limited success (Kreider ef a/., 1986, J. Virol. 59 369; Sterling et al., 1990, J. Virol. 64 6305; Meyers et al., 1992, Science 257 971 ; Dollard et al., 1992, Genes and Development 6 1131 ), papillomaviruses are notoriously refractory to growth in cultured cells (Teichaman and LaPorta, 1987 In "The Papovaviridae", Vol. 2 edited by N. P. Salzman and P. M. Howley p. 109) and this has resulted in a lack of viral reagents which has delayed the analysis of the immune response to PV infection.
The recent advent of recombinant expression systems in vitro has allowed the production of viral proteins encoded by both early and late genes in relatively large amounts and in a purified form (Tindle et al., 1990, J. Gen. Virol. 71 1347; Jarrett et al., 1991 , Virology 184 33; Ghim et al., 1992, Virology 190 548; Stacey et al., 1992, J. Gen. Virol. 73 2337). These systems have, for the first time, allowed the analysis of the host immune response to these viral proteins. Interest in immune responses to the non-structural early open reading frame (ORF) proteins of HPV has centred on HPV-16 E7 because of an apparent association between serum antibodies to this protein and cervical cancer (for a review, see "Immune Response to Human Papillomaviruses and the Prospects of Human Papillomavirus-Specific Immunisation" by Tindle and Frazer In "Human Pathogenic Papillomaviruses" edited by H. zur Hausen, Current Topics in Microbiology Immunology 186, Springer-Verlag, Berlin, 1994).
The immune responses to other HPV early ORF proteins have also been investigated including HPV-16 E6 (Stacey et al., 1992, J. Gen. Virol. 73 2337; Bleul et al., 1991 , J. Clin. Microbiol. 29 1579; Dillner, 1990, Int. J. Cancer 46 703; and Mϋller e. a/., 1992, Virology 187 508), HPV-16 E2 (Dillner et al., 1989, Proc. Natl. Acad. Sci. USA 863838; Dillner, 1990, supra; Lehtinen et al., 1992, J. Med. Virol. 37 180; Mann et al., 1990, Cancer Res 50 7815; and Jenison et al., 1990, J. Infect. Dis. 162 60) and HPV-16 E4 (Kόchel et al., 1991 , Int. J. Cancer 48 682; Jochmus-Kudielka et al., 1989, JA/C/ 81 1698; and Barber et al., 1992, Cancer Immunol. Immunother 35 33).
However, comparison of these studies reveals a lack of correlation between the results of the various assays which have been used in assessing HPV early ORF protein reactivity in serum (Tindle and Frazer, 1994, supra).
In addition, antibodies to other HPV early ORF proteins have not yet been sought with sufficient rigour in large enough numbers of patients to determine their utility as disease markers or as indicators of HPV protein immunogenicity following HPV infection.
For many pathogens including papillomaviruses, a conventional killed or live attenuated vaccine cannot be developed because material is not available, or because the vaccine would be unsafe. However, in many cases, immunogenic B and T epitopes (usually between 4 and 20 amino acids in length) have been defined for proteins encoded by these pathogens and this has increased interest in the formulation of peptide-based vaccines.
Peptides can be synthesised in large quantities with high purity and are chemically well defined. Synthetic peptides can be designed to incorporate any antigenic B and T epitope (Tindle et al., 1991 , Proc. Natl. Acad. Sci. USA 88 5887-5891 ), and exclude potentially deleterious or dangerous functional domains of a protein (Berzofsky, J. A., 1991 , FASEB J. 5 2412-2418). In order to synthesize a highly immunogenic peptide, it is generally considered that uncoupled, carrier free peptide or peptides must contain domains which activate T-helper (Th) cells as well as B-cells so as to facilitate their cognate interaction leading to the development of an effective immune response (Mitchinson, 1971 , Eur. J. Immunol. 1 10-17; Mitchinson, 1971 , Eur. J. Immunol. 1 18-24; Abbas et al., 1985, J. Immunol. 135 1661-1667). In addition, it has recently been shown that cytokines secreted by Th cells are required for cytotoxic T lymphocyte (CTL) activation which activation is important for effective immune control of tumours and viral infections (Matloubian et al., 1994, J. Virol. 68 8056-8063; Batteggay et al., 1994, J. Virol. 68 4700-4704). To this extent, recent experiments have shown that induction of antigen-specific CTL can be effected by linking a Th-
cell epitope directly or indirectly to a CTL epitope.
The identification of defined Th-cell determinants and their use to provide effective carrier help to short constructs representing a B-cell epitope or CTL epitope have made it possible to synthesize putative immunogens. However, the use of Th-cell epitopes in the development of potentially immunogenic chimeric constructs has generally been restricted because of the propensity of Th-cells only to provide 'help' to B-cells and/or CTLs displaying the same processed MHC-restricted form of the antigen. Accordingly, the inclusion of Th-cell epitopes in chimeric constructs comprising B-cell and/or CTL determinants is genetically restricted to only one or a few alleles of the MHC with limited activity across divergent MHC class II haplotypes. Consequently, such chimeric constructs have been considered of limited practical value as vaccines targeted to a majority of an outbred population. Recently, however, universal or promiscuous Th-cell epitopes which can be recognized in the context of several MHC (as well as HLA) haplotypes have been identified in a number of proteins. In particular, Partidos et al. (1991 , J. Gen. Virol. 72 1293-1299) have identified a Th-cell epitope from the fusion protein (F) of measles virus which is immunogenic in a panel of mouse strains of different H-2 types and in seven of 10 humans tested. Reference also may be made to articles by Panina-Bordignon et al. (1989, Eur. J. Immunol. 192237-2242) and Ho et al. (1990, Eur. J. Immunol. 20 483) which are directed to promiscuous Th-cell epitopes from tetanus toxin that were shown to be immunogenic across a wide spectrum of isotypic and allotypic forms of human MHC molecules. In addition, reference may be made to Sinigaglia et al. (1988, Eur. J. Immunol. 18 633-636) which discloses a promiscuous Th-cell epitope from the circumsporozoite protein of Plasmodium falciparum which can function as a helper determinant in a wide range of mouse strains and is recognized by most human class II MHC molecules. Regard may also be had to Fridkis-Hareli et al. (1994, Proc. Natl. Acad. Sci. USA 91 4872-4876) in which Copolymer 1 (Cop 1 ), a synthetic
basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis (EAE), was shown to bind several antigen presenting cells of mouse and human origin irrespective of their MHC class II restrictions. Moreover, several reports have indicated that peptides representing T- and B-cell determinants constituting a chimeric construct do not have to be derived from the same protein or organism. Indeed, Th-cell epitopes derived from tetanus toxin, sperm-whale myoglobin and streptococcal protein have been found capable of imparting help to B-cell determinants taken, respectively, from the human malarial parasite Plasmodium falciparum (Etlinger ef a/., 1990, Science, 249 423-425; Kumar et al., 1992, J. Immunol. 148 1499-1505), foot-and-mouth disease virus (Francis et al., 1987, Nature 300 168-170) and hepatitis B virus (LeClerc et al., 1987, Eur. J. Immunol. 17 269-273). In view of the above, it is known that promiscuous Th-cell epitopes may be incorporated within synthetic chimeric peptides comprising one or more homologous and/or heterologous B-cell determinants in order to bypass haplotype restricted immune responses and thereby alleviate problems associated with vaccinating a genetically diverse outbred population.
In the case of papillomavirus, reference may be made to International Application Publication No WO 92/10513 in which the present applicants disclosed the promiscuous Th-cell minimal proliferative epitope, DRAHYNI, which was derived from human papillomavirus (HPV) E7 protein. This promiscuous epitope either alone or in combination with one or more B- cell epitopes in chimeric constructs was shown to elicit anti-PV proliferative responses in different murine as well as different human MHC backgrounds.
In view of the plethora of Th-cell epitopes defined in the literature which epitopes have been derived from a myriad of different organisms, only a few have been shown to be reactive on several MHC backgrounds (Kaumaya et al., 1993, J. Mol. Recognit. 6 81-94; Domanico et
al., 1993, Eur. J. Immunol. 23 1011-1016; Reece et al., 1994, J. Immunol. Methods 171 241-254).
The current invention arises from the unexpected discovery that peptide sequences within HPV-16 E6, which have substantially different structures to the DRAHYNI epitope of HPV-16 E7, are reactive on several
MHC class II backgrounds. In addition, such HPV-16 E6 peptides when combined with different B-cell epitopes in chimeric peptide constructs elicit specific antibodies which react with peptides containing the B-cell epitopes.
In light of the paucity of promiscuous epitopes reported in the literature, this discovery is surprising because it would not be considered reasonably likely that a small organism such a virus, which consists of only a small number of proteins, will comprise a plurality of promiscuous Th-cell epitopes.
OBJECT OF THE INVENTION
It is therefore an object of the present invention to provide novel peptides comprising promiscuous Th-cell proliferative epitopes which may be utilized to treat HPV infections and which also may be used to provide immunity to HPV infection across a broad spectrum of MHC backgrounds.
It is a further object of the invention to provide novel chimeric peptides comprising promiscuous Th-cell proliferative epitopes in combination with one or more B-cell epitopes and/or one or more cytotoxic
T-cell epitopes which chimeric peptides may be utilized to generate immune responses against the B-cell epitope(s) and/or the cytotoxic T-cell epitope(s).
SUMMARY OF THE INVENTION Accordingly, in one aspect of the invention, there is provided a peptide encoding a promiscuous T helper cell epitope for generating an immune response against papillomavirus, said peptide selected from the group consisting of:-
(i) VYRDGNPYA inclusive of a single amino acid deletion, substitution or addition made therein (SEQ ID NO 1 ); and
(ii) QYNKPLCDLL inclusive of a single amino acid deletion, substitution or addition made therein (SEQ ID NO 2). The term "promiscuous T helper cell epitope" as used herein refers to a T helper cell epitope which is reactive with a plurality of different MHC class II haplotypes.
The invention also contemplates 'peptide homologs' of peptides according to SEQ ID NO 1 and SEQ ID NO 2. Thus, the invention also includes within its scope peptides which are functionally similar to those defined in SEQ ID NO 1 and SEQ ID NO 2. For example, one of skill in the art will appreciate that conservative amino acid substitutions can be made in peptides according to SEQ ID NO 1 and SEQ ID NO 2 (parent peptides) and that such substituted peptides will retain the functional characteristics of the parent peptides.
The peptides of the invention may be prepared using any suitable procedure. Preferably, such peptides are synthesized either manually or by using an automated peptide synthesiser.
Peptides according to SEQ ID NO 1 and SEQ ID NO 2 and peptide homologs thereof may be synthesised using solution synthesis or solid phase synthesis as described, for example, in Chapter 9 entitled "Peptide Synthesis" by Atherton and Shephard which is included in a publication entitled "Synthetic Vaccines" edited by Nicholson and published by Blackwell Scientific Publications.
Alternatively, a peptide in accordance with the invention may be prepared by a procedure including the steps of: (a) ligating a nucleotide sequence encoding a peptide according to SEQ ID NO 1 , SEQ ID NO 2 or peptide homolog thereof into a suitable expression vector to form an expression construct;
(b) transfecting the expression construct into a suitable host cell; (c) expressing the recombinant peptide; and
(d) isolating the recombinant peptide.
As used in this specification, an expression construct is a nucleotide sequence comprising a first nucleotide sequence encoding a peptide according to SEQ ID NO 1 , SEQ ID NO 2 or peptide homolog thereof wherein said first sequence is operably linked to regulatory nucleotide sequences (such as a promoter and a termination sequence) that will facilitate expression of said first sequence. Both constitutive and inducible promoters may be useful adjuncts for expression of the peptides according to the invention. The expression construct preferably includes a vector, such as a plasmid cloning vector. A vector according the invention may be a prokaryotic or a eukaryotic expression vector, which are well known to those of skill in the art.
Suitable host cells for expression may be prokaryotic or eukaryotic. One preferred host cell for expression of a peptide according to the invention is a bacterium. The bacterium used may be Escherichia coli. The recombinant peptide may be conveniently prepared by a person skilled in the art using standard protocols as for example described in Sambrook et al. (1989, second edition, Cold Spring Harbor Laboratory Press, in particular Sections 16 and 17).
The term "nucleotide sequence" as used herein designates mRNA, RNA, cRNA, cDNA or DNA.
A nucleotide sequence encoding the peptides of the invention may be conveniently prepared by taking advantage of the genetic code and synthesising, for example, by use of an oligonucleotide sequencer, a sequence of nucleotides which when translated by a host cell results in the production of a peptide according to SEQ ID NO 1 , SEQ ID NO 2 or peptide homolog thereof.
It will be understood that each of the peptides according to SEQ ID NO 1 and SEQ ID NO 2 comprises minimal T helper cell proliferative sequences which are considered to incorporate the key "anchor" amino acid residues required for binding an MHC class II molecule. However, it should be noted that peptides associated with MHC class II molecules may
comprise 10 to 34 amino acid residues, and the optimal length of a T helper cell epitope has been defined crystallographically and otherwise to be between 13 and 20 amino acids (Appella et al., 1995, EXS. 73 105-119 which is hereby incorporated by reference). Accordingly, the invention contemplates a peptide of 10 to 34 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the amino acid sequence defined by SEQ ID NO 1 or peptide homolog thereof and/or the amino acid sequence defined by SEQ ID NO 2 or peptide homolog thereof.
In yet another aspect, the invention provides a peptide of 13 to 20 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the amino acid sequence defined by SEQ ID NO 1 or peptide homolog thereof and/or the amino acid sequence defined by SEQ ID NO 2 or peptide homolog thereof.
It will be appreciated from the prior art referred to above and from the exemplification of the invention described hereinafter that such larger peptides will also be expected to behave as promiscuous T helper cell epitopes.
Thus, in a further aspect of the invention, there is provided a chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide in accordance with SEQ ID NO 1 or peptide homolog thereof linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
According to yet another aspect of the invention, there is provided a chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide in accordance with SEQ ID NO 2 or
peptide homolog thereof linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
Preferably, the chimeric peptide construct comprises between 10 and 34 amino acids. More preferably, the chimeric peptide construct comprises between 10 and 20 amino acids.
B-cell epitopes may be selected from any suitable source including but not necessarily limited to pathogenic organisms such as pathogenic viruses. A suitable pathogenic virus which may be used as a source of B-cell epitopes includes papillomavirus. For example, the B-cell epitopes may comprise HPV16 E7 B-cell epitopes which include QAEPD, IDGP, EYMLD and YMLD. Alternatively, suitable B-cell epitopes that may be selected from HPV 18 E7 epitopes include DEIDGVNHQL and SEENED.
CTL epitopes are preferably selected from a tumor or viral source. In the case of a virus, the virus may be a papillomavirus. In such a case, the CTL epitope may be selected from human CTL epitopes in HPV16
E6 and HPV16 E7 (Ressing et al. 1995, J. Immunol. 154 5934-5943 which is hereby incorporated by reference) or the murine CTL epitope RAHYNIVTF in HPV16 E7 (Ossevoort et al., 1995, J. Immunother. 18 86-94 which is hereby incorporated by reference). Alternatively, the CTL epitope may comprise a measles protein CTL epitope as described in an article by Hsu et al. (1996, Vaccine 14 1159-1166 which is hereby incorporated by reference) or an Adenovirus CTL epitope as described by Toes et al. (1996,
Proc. Natl. Acad. Sci. U.S.A. 93 7855-7860 which is hereby incorporated by reference).
Representative peptides which fall within the scope of the invention include the following:
N1 - A - X - A2 (1 )
N2 - X - N3 (2) N1 - A1 - X - A2 - N4 (3)
N2 - X - A2 (4)
A1 - X - N3 (5)
A1 - X - A2 - N4 (6)
N1 - A1 - N4 - A1 - X - A2 (7)
N1 - A1 - N4 - X - N3 - A2 - N5 (8) N1 - A1 - N4 - A2 - N2 - X - A2 (9)
In the above formulae (1) through (9): X denotes a promiscuous T helper cell epitope comprising peptides selected from SEQ
ID NO 1 , SEQ ID NO 2 or peptide homologs thereof; N1 , N4 and N5 represent B-cell epitope or CTL epitope sequences that may be linked to said promiscuous epitope sequences indirectly through intervening sequences of amino acids that are not B-cell or CTL epitope sequences such as A1 and A2.
In some cases, the B-cell or CTL epitope sequence may be linked directly to the promiscuous T helper epitope sequence and in such a case in a first situation the terminal amino acid of the B-cell or CTL epitope sequence and the first amino acid of said promiscuous epitope sequence may be merged. In other cases, in a second situation the last amino acid of the promiscuous T helper epitope sequence and the first amino acid of the B-cell or CTL epitope sequence may also be merged. In this embodiment therefore N2 represents a B-cell or CTL epitope sequence which refers to the first situation and N3 represents a B-cell or CTL epitope sequence that represents the second situation.
The sequences according to SEQ ID NO 1 and SEQ ID NO 2 have been identified as corresponding to two major T helper cell epitopes in the E6 open reading frame (ORF) of HPV16. SEQ ID NO 1 and SEQ ID NO
2 correspond respectively to amino acids 60-68 and 98-107 of the E6 ORF.
Peptides according to SEQ ID NO 1 and SEQ ID NO 2 are each capable of eliciting strong antibody responses to HPV16 E6 challenge across a wide range of MHC class II backgrounds. In addition, chimeric constructs in accordance with the present invention comprising peptides according to SEQ ID NO 1 and SEQ ID NO 2 may facilitate the production
of antibody to several B-cell epitopes simultaneously as well as several CTL epitopes simultaneously.
The invention also includes within its scope an immunogenic composition comprising one or more of the abovementioned peptides and a suitable adjuvant or delivery vehicle.
Suitable adjuvants may be selected from Freunds Complete Adjuvant, Freunds Incomplete Adjuvant, QuilA and saponins generally. Preferably, the adjuvant is capable of eliciting CD8+ MHC class I restricted cytotoxic T lymphocytes. Suitable delivery vehicles in which the peptides of the invention may be delivered into a host animal include, but are not necessarily limited to, liposomes, membranous vehicles and microspheres which are well known to those skilled in the art. Alternatively, the delivery vehicle may be an immunostimulating complex (ISCOM). Such ISCOM may be prepared using any suitable technique. For example, reference may be made to Morein et al., 1984, supra, Morein, B., 1988, Nature 332 287-288, and Lόvgren and Morein, 1991 , Mol. Immunol. 28 285-286 which are hereby incorporated by reference. Suitable methods for incorporation of peptides into ISCOMs are also known and these include coupling peptides to influenza virus envelope glycoproteins which have already been incorporated into ISCOMs (Lovgren et al., 1987, supra; Lovgren and Larsson, supra), or coupling cysteine- containing peptides to preformed influenza ISCOMs using a heterobifunctional reagent (Larsson et al., 1993, J. Immunol. Methods 162 257-260 which is hereby incorporated by reference). Alternatively, peptides may be incorporated into ISCOMs by copolymerisation with the lipid binding peptide LAP20 (Fernando et al., 1994, In "Vaccines 94", pp 327-331 , Cold Spring Harbour Laboratory Press).
A preferred delivery vehicle contemplated by the invention is a chimeric VLP including a modified viral capsid protein having one or more peptides of the invention fused thereto. In one form, the chimeric VLP may comprise the modified viral capsid protein alone. Alternatively, the chimeric
VLP may comprise the modified viral capsid protein in association with one or more other viral capsid proteins which may be required for assembly of the chimeric VLP.
The modified viral capsid protein may be prepared from any parent viral capsid protein, including a natural viral capsid protein, which when fused with the one or more peptides results in a modified viral capsid protein which is capable of incorporating into a chimeric VLP. The parent viral capsid protein includes, but is not limited to, a papillomavirus capsid protein or a parvovirus capsid protein. Accordingly, the parent viral capsid protein may comprise an L1 protein or an L2 protein of a papillomavirus. In the case of parvovirus, the parent viral capsid protein may comprise a VP2 capsid protein.
In view of the above, it is well known that foreign peptides can be incorporated into a viral capsid protein to produce chimeric VLPs which can be used to present foreign antigens to an immune system. Suitable methodologies for production of such chimeric VLPs are also known. For example, the peptides of the invention may be fused to a papillomavirus 1 L1 capsid protein as described, for example, in Muller et al (1997, Virology 23493-111 ), or fused to a papillomavirus L2 capsid protein as described, for example, in United States Patent No 5,618,536 (Lowy et al) which is hereby incorporated by reference, or fused to a porcine parvovirus VP2 capsid protein as described, for example, in Sedlik et al (1997, Proc. Natl. Acad. Sci. USA 94 7503-7508) which is hereby incorporated by reference.
The above exemplary methods of producing chimeric VLPs essentially involve construction of a synthetic DNA molecule encoding the modified viral capsid protein and subsequent expression of this protein in a suitable host cell to facilitate assembly of the chimeric VLP. Depending on the modified viral capsid protein being expressed, such expression may require co-expression of one or more other viral capsid proteins for assembly of the chimeric VLP.
The synthetic DNA molecule may be prepared using any
suitable method for altering DNA. Such methods are well known to those of skill in the art and are described for example in the relevant sections of CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel, et al., eds.) (John Wiley & Sons, Inc. 1995) and of Sambrook, et al., MOLECULAR CLONING. A LABORATORY MANUAL (Cold Spring Harbor Press, 1989) which are hereby incorporated by reference. Alternatively, suitable methods for altering DNA are set forth, for example, in U.S. Patent Nos 4,184,917, 4,321 ,365 and 4,351 ,901 which are hereby incorporated by reference.
The synthetic DNA molecule may be ligated into a suitable expression vector to produce a recombinant expression vector may be introduced subsequently into a host cell for expression of the modified viral capsid protein. Preferably, the expression vector is a baculovirus expression vector and the host cell is a Spodoptera frugiperda 9 (Sf-9) insect cell. BRIEF DESCRIPTION OF THE DRAWINGS In order that the invention may be readily understood and put into practical effect, particular preferred embodiments will now be described by way of example with reference to the following figures in which:
FIG. 1 refers to a set of overlapping peptides (termed GF51- GF66) spanning the putative HPV16 E6 protein molecule; FIG.2 illustrates the overlapping pattern of the peptides of FIG.
1 relative to the amino acid sequence of HPV16 E6 protein;
FIG. 3A is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized subcutaneously with saline: CFA, and challenged with individual HPV16 E6 peptides; FIG. 3B is a bar graph showing the in vitro proliferative repsonse of LNCs from H-2b mice immunized subcutaneously with saline: CFA, and challenged with PPD + individual HPV16 E6 peptides;
FIG. 4A is a bar graph showing the in vitro proliferative response of LNCs from H-2 mice immunized with peptides GF51-GF54; FIG. 4B is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized with peptides GF55-GF58;
FIG. 4C is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized with peptides GF59-GF62;
FIG. 4D is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized with peptides GF63-GF66; FIG. 5A illustrates the in vitro proliferative response of LNCs from H-2 mice immunized subcutaneously with an equimolar mixture of peptide GF56;
FIG. 5B is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized subcutaneously with an equimolar mixture of peptide GF57;
FIG. 5C is a bar graph showing the in vitro proliferative response of LNCs from H-2 mice immunized subcutaneously with an equimolar mixture of peptide GF61 ;
FIG. 5D is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized subcutaneously with an equimolar mixture of peptide GF66;
FIG. 5E is a bar graph showing the in vitro proliferative response of LNCs from H-2b mice immunized subcutaneously with an equimolar mixture of peptide GF51 ; FIG. 6A is a bar graph showing the T-proliferative response of
LNCs from C57BL/6 (H-2b) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
FIG. 6B is a bar graph showing the T-proliferative response of LNCs from B10 (H-2a) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
FIG. 6C is a bar graph showing the T-proliferative response of LNCs from B10 (H-2k) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
FIG. 6D is a bar graph showing the T-proliferative response of LNCs from B10 (H-2d) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides; FIG. 6E is a bar graph showing the T-proliferative response of
LNCs from B10 (H-2h2) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
FIG. 6F is a bar graph showing the T-proliferative response of LNCs from B10 (H-2h4) mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides;
FIG. 7 illustrates the mapping of the minimal T-cell proliferative epitope in the GF57 peptide of HPV16E6 protein; FIG. 8A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF57, and challenged with 20 μg/mL GF57 overlapping truncated peptides;
FIG. 8B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF57, and challenged with 5 μg/mL GF57 overlapping truncated peptides;
FIG. 9 illustrates the mapping of the minimal T-cell proliferative epitope in the GF61 peptide of HPV16E6 protein; FIG. 10A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF61 , and challenged with 20 μg/mL GF57 overlapping truncated peptides;
FIG. 10B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF61 , and challenged with 5 μg/mL GF57 overlapping truncated
peptides;
FIG. 11A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 20 μg/mL GF57 overlapping truncated peptides;
FIG. 11 B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 5 μg/mL GF57 overlapping truncated peptides; FIG. 12A is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 20 μg/mL GF61 overlapping truncated peptides;
FIG. 12B is a bar graph showing the in vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with 5 μg/mL GF61 overlapping truncated peptides;
FIG. 13A is a bar graph showing the effect of 'VYRDGNPYA' Th-epitope on the antibody response to ΕYMLD' B-epitope; FIG. 13B is a bar graph showing the effect of 'QYNKPLCDLL'
Th-epitope on the antibody response to ΕYMLD' B-epitope.
FIG. 13C is a bar graph showing the effect of 'VYRDGNPYA' Th-epitope on the antibody response to 'QAEPD' B-epitope;
FIG. 13D is a bar graph showing the effect of 'QYNKPLCDLL' Th-epitope on the antibody response to 'QAEPD' B-epitope; and
FIG. 14 is a map of recombinant vector pVLBPVI L1/Thprom- QAEPD.
PREFERRED EMBODIMENTS EXAMPLE 1 Identification of T-proliferative epitopes in H-2b mice MATERIALS AND METHODS
Buffers
Unless otherwise specified, buffers were prepared according to Sambrook et al. (1989, MOLECULAR CLONING. A LABORATORY
MANUAL, second edition, Cold Spring Harbor Laboratory Press) and
Ausubel et al. (1995, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc.).
Antigens
HPV16 E6 and HPV16 E7 proteins were produced as MS2- fusion proteins from a heat-inducible phage promoter in a pPLc24 expression vector (provided by L. Gissmann, DKFZ, Heidelberg, Germany) in E. coli C600/537 by sequential urea extraction, as described by Seedorf et al. 1987.
The expression vector pPLc24 allows the expression of inserts fused to the N-terminal part (the first 98 aas) of the MS2 polymerase under the control of the lambda PL promoter which does not contain the cl gene coding for repressor (Remaut et al., 1981 , Gene 15 81-93; Remaut et al., 1983, Gene 22 103-113; Remaut et al., 1983, Nucleic Acids Res. 11 4677- 4688). But since the E. coli C600/537 strain harbors a temperature-sensitive cl repressor gene of phage lambda on a multicopy plasmid conferring kanamycin resistance, expression of the pPLc24 vector was induced in log phase cells by incubating at 42°C for 3 hrs. After induction, cells of a 1 L LB broth culture were first washed with Bacterial Wash Buffer, then lysed in 40 imL Bacterial Lysis Buffer in the presence of 8 mg lysozyme and incubated, with shaking, at 37°C for 30 min. Next, MS2-replicase fusion proteins were partly purified by the addition of 0.1% Triton X-100. After sonicating (on ice) and stirring for 30 min at 37°C, the lysate was cleared by centrifugation at 40,000g for 15 min. The supernatant was removed and stored at -70°C and the pellet was successively extracted with 30 mL Phosphate Buffered Saline (PBS) containing 0.1 % Triton X-100, then with 30 mL 3M Urea, and finally with 30 mL 7M Urea. Accompanying all these final 3 steps are sonication, further stirring at 37°C (or at room temperature, RT, in case of urea extraction) and centrifugation; and each time the supernatant was removed
and stored away at -70°C. The final pellet was also stored at -70 O for further testing. After performing SDS-PAGE, Western Blotting and estimating the percentage of purity of the 7M Urea supernatant, the latter was dialyzed against PBS at 4°C, using a 12,000 mwt cut off membrane. SDS-PAGE / Western Blotting
SDS-PAGE was performed to estimate the purity and yield of the fusion proteins. Consequently, the fusion proteins (-20 μg protein per lane) were diluted in 2x concentrated SDS Sample Buffer containing 0.2 M Dithiothreitol (DTT), heated for 5min at 100°C and separated on a 12% polyacrylamide gel (Laemmli, 1970, Nature 227 680), at 200 V using SDS- PAGE Electrode Running Buffer. This was done in duplicate: one gel was stained with Coomassie Blue, destained with Methanol/Acetic Acid (Destains 1 and 2) and then dried on a slab gel dryer (Drygel Sr. Model SE 1160, Hoefer Scientific Instruments, San Francisco) for 1 hr at 80°C. The other gel was transferred by Western Blotting onto a nitrocellulose membrane using SDS Transfer Buffer at a 100 V according to standard procedures. The blot was blocked with 5% skim milk powder in PBS Blocking Buffer (PBS/milk) at 4°C o/n. The second day, it was incubated at RT for 1-1.5 hr with a rabbit polyclonal anti HPV16 E6/MS2 antiserum (previously prepared in our laboratory) diluted 1 :200 in PBS/milk. This was followed by 3 washes (each for 10 min) with the following Wash Buffer: 5% skim milk powder in PBS + 0.1% Triton X-100.
Following washing; a second antibody, Horse radish peroxidase linked sheep anti-mouse immunoglobulin, diluted 1 :1000 in PBS/milk was added and the blot was incubated at RT for another 1-1.5hr followed by the washing procedure mentioned above. Finally the specific bands were visualized by the Di-aminobenzidine (DAB) substrate reaction in the presence of H202. The reaction was stopped by rinsing the blot with distilled water (dH20) and air drying. Protein Concentration Determination
Protein concentration estimation was performed using the
Pierce BCA Protein Assay Reagent commercial kit. The kit contains two reagents: Reagent A (Base reagent) which contains sodium carbonate, sodium bicarbonate, bicinchoninic acid (BCA) detection reagent and sodium tartrate in 0.2 N NaOH; and Reagent B which is a 4% copper sulfate solution.
Ten microlitres of sample (or bovine serum albumin, BSA, standard or blank) were mixed with 200 μL Working Reagent (50 parts Reagent A + 1 part Reagent B) in microtiter plate wells (usually done in triplicates). After incubating the plate at 37°C for 30 min, absorbance at 540 nm (OD540) was determined by spectrophotometry using a Titertek Multiskan reader.
The protein concentration was estimated by comparison of the mean OD540 (mean of 3 wells) obtained with the sample, with that obtained with the BSA standards. Mice
Generally, inbred mouse strains were obtained from the Animal Resources Centre (Perth, Australia) and were used at 7-10 weeks of age. In regard to inbred Balb/c mice, these were obtained from the same source and were used at 4-12 weeks of age. Synthetic Peptides
Overlapping synthetic peptides (GF51-GF66) covering the entire HPV16 E6 ORF were used as antigens. These peptides were synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry on an Applied Biosystems 431 A peptide synthesizer. After obtaining the 'peptide- resin' conjugates, the actual peptide was next cleaved from its resin by the addition of thioanisole and ethanedithiol, and then ether purified.
Briefly, 100 mg of resin conjugate, 100 μL dH20, 100 μL thioanisole and 50 μL ethanedithiol were mixed in a glass tube. To this mixture, few phenol crystals dissolved in 2 mL trifluoroacetic acid (TFA) were added and the whole mixture was left to stir at RT for 1.5-2.0 hr. The resin solution was then filtered through a coarse sintered glass funnel, into 40 mL
of cold ether in a 50 mL Falcon tube, and spun down at 4°C, for 5 min, at a speed of 1000g. After discarding the supernatant, the peptide pellet was precipitated 5 more times, each time with 20 mL of cold ether. Finally, the peptide crystals were allowed to air dry o/n and then stored at -70°C. Series of peptides, truncated by 1 aa from either the N-terminal or the C-terminal, and covering the whole length of peptides GF57 and GF61 were synthesized by Chiron Mimotopes Peptide Systems PTY, LTD (Victoria, Australia). The HPLC profile, amino acid composition, toxicity and mitogenicity of all peptides were checked. HPV 16 E6 Protein
HPV16 E6 protein was produced as an MS2 fusion protein as described above. Fusion protein was then dialyzed against PBS for use in proliferation assays.
Lymph Node Cell (LNC) Proliferation Assays Mice were immunized subcutaneously in the base of the tail with about 50 μg of peptide emulsified in Complete Freund's Adjuvant (H37 Ra. CFA, Difco). Nine days later, the inguinal and periaortic lymph nodes were collected from the immunized mice, and a suspension of draining LNCs was prepared after two washes in Dulbecco's Modification of Eagle's Medium (DMEM) supplemented with 100 lU/mL Penicillin, 100 μg/mL Streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, 20 mM HEPES buffer and 50 μM β-mercaptoethanol (complete DMEM, cDMEM).
The LNCs suspension was prepared at a concentration of 2x106 cells per mL in cDMEM containing 10% FCS. A four day proliferation assay (at 37°C) (Good et al. , 1987, Science 235 1059-1062) was conducted in peptide-coated microtiter plates where every peptide-coated well was allowed to interact with 4x105 LNCs/mL (200 μL of LNCs suspension). Wells coated with Purified Protein Derivative (PPD) or cDMEM were used as positive and negative controls, respectively. Next, proliferation was quantified by [3H] Thymidine incorporation: the LNCs were pulsed with 1 μCi of [3H] Thymidine (Amersham) per well; and 16 hr later, the amount of [3HJ
Thymidine uptaken by the cells DNA was determined using an LKB beta- plate system reader.
RESULTS
Identification of T-proliferative epitopes in H-2b Mice A panel of overlapping E6 16-23 mer peptides covering the whole length of the HPV16 E6 molecule (FIGS. 1 , and 2) was tested for lack of toxicity and mitogenicity. For this, lymph-node cells (LNCs) from H-2b mice immunized with saline: CFA were challenged in vitro with individual HPV16 E6 peptides with or without purified protein derivative (PPD), respectively. LNC proliferation with PPD was expected since PPD of tuberculin is a component of CFA. According to FIGS. 3A and 3B, none of the peptides seemed to be toxic or mitogenic. Using this panel of non-toxic, non-mitogenic HPV16 E6 peptides, three potential murine T-proliferative epitopes in HPV16 E6 were identified, in T-proliferation assays in which LNCs from peptide immunized H-2b mice were challenged in vitro with whole protein and individual peptides.
Initially, four groups of C57BL/6 (H-2b) mice were immunized with equimolar mixes of peptides GF51 - GF54, GF55 - GF58, GF59 - GF62 or GF63 - GF66 respectively in CFA. Pooled LNCs from each group were challenged in vitro with individual peptides at 2 or 20 μg/mL.
Peptide GF57 elicited strong proliferation and GF56 weaker proliferation in LNCs from the GF55 - GF58 immunized group (FIGS.4A, 4B, 4C and 4D). Moreover, a proliferative response was elicited with peptide GF61 in LNCs from the GF59 - GF62 immunized group (FIGS. 4A, 4B, 4C and 4D). No further peptides from GF51 - GF66 series induced proliferation in assays using LNCs from appropriately immunized H-2b mice.
To determine the minimal dose of peptide which would elicit proliferation, C57BL/6 mice were then immunized with mixtures of peptides GF56, GF57, GF61 and irrelevant peptide GF66 in CFA. LNCs from these mice were challenged in vitro with individual peptides at different concentrations (20 μg/mL, 10 μg/mL, 5 μg/mL, 2.5 μg/mL, 1.25 μg/mL and
0.63 μg/mL). FIGS. 5A, 5B, 5C, 5D and 5E shows that the LNCs response to peptides GF56, GF57 and GF61 decreased with decreasing concentration of the challenging peptide and that the minimal dose of challenging peptide which would still elicit good proliferation is 5 μg/mL. No response to challenging control peptides GF66 or GF51 was noticed.
To examine the major histocompatibility complex (MHC) restriction of the response to the immunogenic peptides from HPV16 E6, C57BL/6 mice (H-2b) and B10 congenic mice differing only at the major histocompatibility complex (MHC) class 2 locus; B10A (H-2a), B10BR (H-2k), B10D2 (H-2d), B10A.2R (H-2h2) and B10.4R (H-2h4) were immunized with mixtures of peptides GF56, GF57 and GF61. LNCs from all strains of immunized B10 congenic mice showed strong proliferative response to peptide GF56. Immunized C57BL/6 mice responded to all three peptides GF56, GF57 and GF61. None of the mice responded to the control peptide GF51 (FIGS. 6A, 6B, 6C, 6D, 6E and 6F). Hence, peptides GF57 and GF61 each contains a T-proliferative epitope(s) reactive in H-2b mice; while peptide GF56 contains a "promiscuous" T-epitope, reactive on several murine MHC backgrounds.
To determine the minimal T-proliferative epitopes sequences, LNCs from GF57 immunized mice were challenged in vitro with a series of overlapping peptides, truncated by 1 amino acid from either the N-terminal or the C-terminal, and covering the whole length of peptide GF57 (FIG. 7) at different concentrations (20 μg/mL, 5 μg/mL, 2 μg/mL and 0.5 μg/mL). LNCs stimulated with peptides GF57/1-3 and GF57/16-24 proliferated significantly, indicating that the consensus sequence "VYRDGNPYA" was the minimal proliferative epitope (FIGS. 7, 8A and 8B).
Similarly, a series of N-terminal or C-terminal truncated overlapping peptides, covering the whole length of peptide GF61 was used in LNC proliferation assays to recall T-cell activation from mice immunized with GF61 (FIG. 9). The LNCs proliferated significantly when challenged in v/ϊro with peptides GF61/1-3, GF61/14-16 and GF61/19, indicating that the
consensus sequence "QYNKPLCDLL" was the minimal proliferative epitope in peptide GF61 (FIGS. 9, 10A and 10B). It is noteworthy that the LNCs did not proliferate when challenged with peptides GF61 /17-18, probably because of the Leucine and Isoleucine being two hydrophobic residues at the C- terminal end of the peptide molecule competing to fit into the T-cell receptor groove on the antigen presenting cell (APC) and resulting in an unstable peptide molecule.
For both of these experiments a control group of mice was immunized with the irrelevant peptide GF51 , and LNCs challenged in vitro with either the GF57 or the GF61 series of overlapping peptides. However, no response with any of the truncated peptides was noted (FIGS. 11 A, 11 B,
12A and 12B).
Confirmation of the T-Helper Epitopes in H-2b Mice To determine whether the defined T-proliferative epitopes can provide help for the production of specific antibodies to a characterized B-cell epitope, H-2b mice were immunized three times at two weekly intervals with a subunit vaccine consisting of synthetic peptides containing either VYRDGNPYA or QYNKPLCDLL T-epitope linked to known HPV16 E7 B-cell epitopes (Tindle et al, 1990, J. Gen. Virol. 71 1347-1354):
EYMLD AG VYRDGNPYA AG QAEPD or
B B
EYMLD AG QYNKPLCDLL AG QAEPD
B B
wherein AG denotes a neutral spacer between the epitope sequences. Ten days after the third immunization, sera were then collected from peripheral blood and tested in ELISA assays against peptides containing epitopes QAEPD and EYMLD. These tests showed that after
vaccination with either of these synthetic peptides, the mice developed antibodies only to QAEPD. The absence of anti-EYMLD antibodies in these sera suggests the possibility that the H-2b mice have seen the QAEPD as an immunodominant B-epitope and directed most of their humoral immune response to generate antibodies to it. Control mice immunized with either EYMLD alone, QAEPD alone or T-epitope alone did not produce any antibody to either EYMLD or QAEPD (FIGS. 13A, 13B, 13C and 13D).
Hence, the defined proliferative T-epitopes in HPV16 E6 are actually functional T-helper epitopes that can be used for eliciting cognate interaction between T- and B-lymphocytes for the production of antibody against the B-cell epitopes. DISCUSSION
In this study, we have defined three murine T-cell epitopes in the context of H-2b haplotype, by observing T-cell proliferation using cells from HPV16 E6 peptide immunised C57BL/6 mice. For this purpose, a set of overlapping peptides (GF51-GF66) spanning the entire HPV16 E6 sequence was used.
The , 51DFAFRDLCIVYRDGNPYA68 ' peptide GF56 was shown to contain a promiscuous T-proliferative epitope, reactive on several MHC backgrounds.
Using a series of overlapping, truncated E6 peptides in T- proliferation assays to recall T-cell activation, we were able to define the minimal proliferative sequences of two T-epitopes in HPV16 E6 protein: ' 60VYRDGNPYA68 ' and ' 98QYNKPLCDLL107 '. When H-2b mice were immunized with an equimolar mixture of peptides GF57 and GF61 (FIGS. 6A - 6F), 'VYRDGNPYA' in GF57 seemed to be the dominant epitope since LNC proliferation after in vitro challenge with GF57 was stronger than with GF61. T-epitope immunodominance depends on several mechanisms such as antigen processing, competition for binding to MHC, hindering structures outside the minimal epitopes and structures of the T-cell site (Partidos and Steward, 1992, J. Gen. Virol. 73
1987-1994; Boehncke et al., 1993, ; Grewal et al., 1995; Moudgil et al., 1996).
Although 'VYRDGNPYA' is a common sequence to both peptides GF56 and GF57, peptide GF57 triggered in H-2b mice a stronger proliferative response than GF56. However, the proliferative responses of the other tested strains of mice was stronger with GF56 than with GF57. This finding would suggest that the flanking sequences outside the minimal epitope could influence response as observed by other scientists (Gammon et al., 1987, Immunological Reviews 98 53-73; Partidos and Steward, 1992, supra; Brett et al., 1988, J. Exp. Med. 168 357-373; Vacchio et al., 1989, J.
Immunol. 1432814-2819). It is also possible that GF56 contains a T-epitope other than 'VYRDGNPYA', which is proliferative on several MHC haplotypes.
We have also demonstrated that immunisation of mice with either VYRDGNPYA' or 'QYNKPLCDLL' joined to B-cell epitopes will elicit specific antibodies which will react with peptides containing the B-cell epitope. This suggests that these two sequences are T-helper-cell- stimulating epitopes that can be used for eliciting cognate interaction between T- and B- lymphocytes for the production of antibody against the B- epitopes. It is worth mentioning that both 'VYRDGNPYA' and
'QYNKPLCDLL' are located adjacently to 'Cys-X-X-Cys' motifs, 'VYRDGNPYA' being localised to the first loop formed by the four 'Cys-X-X- Cys' motifs present in HPV16 E6 and 'QYNKPLCDLL' present in the region between the loops. It is believed that these motifs play an important role in the function of the E6 protein. They are involved in metal binding and have been shown to be involved in transcriptional regulation (Lamberti et al., 1990, EMBO J. 9 1907-1913) and contribute to E6-mediated transformation by binding to p53 and enhancing its degradation. It appears that the putative p53-binding domain of E6 identified by Crook et al (1991 , Cell 67 547-556) can be localised to the second loop formed by the four 'Cys-X-X-Cys' motifs. However, the region necessary to direct p53 degradation resides in the first
loop and sequences N-terminal to this. The region between the loops functions as a spacer to keep the loop apart.
In summary, 'VYRDGNPYA' and 'QYNKPLCDLL' are capable of eliciting cognate interaction between T- and B-lymphocytes and therefore may be used generically to produce a subunit synthetic peptide vaccine consisting of a promiscuous T helper cell epitope according to the invention, in combination with one or more B-cell epitopes and/or one or more CTL epitopes, to generate immune responses against the B-cell and/or CTL epitopes. Moreover, the defined promiscuous T-helper epitopes in HPV16 E6 protein are reactive with a plurality of different MHC class II haplotypes and thus may be used in a vaccine construct to treat HPV infections by providing immunity to HPV infection across a broad spectrum of MHC backgrounds.
It is important to note though, that LNCs from H-2b mice immunized with HPV16 E6/MS2 protein failed to proliferate when challenged in vitro with E6 peptides GF51-GF66. This result may be due to unfolding and antigen processing of the protein molecule. The existence of MHC- specific hindering structures on the naturally processed fragments that are not present on synthetic peptides comprising little more than the antigenic site may interfere with binding to la or to the T-cell receptor (TCR) (Brett et al., 1988, supra; Partidos and Steward, 1992, supra; Sercarz et al., 1993; Moudgil et al., 1996, supra). This may have important implications for the design of peptide vaccines that, although immunogenic themselves, may generate a T-cell response that is poorly reactive to the native molecule.
EXAMPLE 2 Preparation of a chimeric VLP comprising VYRDGNPYA and QAEPD fused to the C-terminus of BPV1 L1
Construction of recombinant baculovirus transfer vector Primers 5'-CCGCAATCCATGGCGTTGTGGCAACAAGGCC- AGAAGC-3' and 5'-CCGGAATTCTTATTTTTTATCAGGTTCAGCTT- GAGCATAAGGATTGCCATCCCGATAAACTCCTGCCCCTTGCTGTGCT
AAAAATCTTCTTCC-3' may be utilized to allow amplification by PCR of a hybrid nucleotide sequence encoding a modified BPV1 L1 gene in which a chimeric peptide comprising the minimal promiscuous epitope VYRDGNPYA and the HPV16 E7 B-cell epitope QAEPD, is fused to the C-terminus of the BPV1 L1 sequence. This fusion would result in deletion of nucleotides from 7625 downstream of the BPV1 nucleotide sequence. The above primers would also facilitate insertion of a stop codon, and one flanking BamYW site at the 5' end and a flanking ΞcoRI site at the 3' end of the hybrid nucleotide sequence. After amplification, the PCR products could be digested with SamHI and EcoRI and inserted subsequently into the baculovirus transfer vector pVL1393 (Pharmingen) at the BamYW and EcoRI sites thereof before transformation of DH-5α cells. Recombinant clones having the correct sequence could be confirmed by restriction endonuclease and nucleotide sequence analyses. A map of a recombinant baculovirus transfer vector pVLBPV1 L1/Thprom-QAEPD so produced is shown in FIG. 14.
Production of recombinant baculoviruses Recombinant baculoviruses could be produced according to Pharmingen's BaculoGold™ transfection kit. Briefly, Spodoptera frugiperda 9 (Sf-9) insect cells are co-transfected with BaculoGold™ linearized DNA and the recombinant transfer vectors. Preferably, plaque purification is used to ensure no non-recombinant (wild-type) plaques are detected. High-titer (> 108/mL virus particles) stocks of recombinant baculoviruses are obtained subsequently by two rounds of amplification.
Production and purification of chimeric VLPs Procedures for production and purification of VLPs have been described in detail previously (Qi et al., 1996, Virology 216 35-45 which is hereby incorporated by reference). In general, Sf-9 insect cells are infected either with recombinant baculovirus at a multiplicity of infection of 10 plaque- forming-units (PFU) per cell, and incubated at 27°C for 72 h. The cells are the n centrifuged, washed with PBS once, and resuspended in an appropriate amount of PBS in the presence of 2 mM PMSF. The cell
suspension is then homogenized with a dounce homogenizer (tight pestle) by 50 strokes on ice and then centrifuged at 3000 rpm for 10 min at 4°C to separate the nuclear fraction. The nuclear pellet is then resuspended in an appropriate resuspension buffer and sonicated for 45 sec on ice. The nuclear suspension is then loaded onto a 20% sucrose cushion and centrifuged at 26,000 rpm in a Beckman SW-26 rotor at 4°C for 2 h. The pellets are then resuspended in resuspension buffer and sonicated again for another 45 sec. The resulting sonicate is then mixed with CsCI and centrifuged at 21 °C in a Beckman SW 41 rotor for 20 H. A band at the CsCI density of about 1.30 g/mL is then collected and dialysed against PBS. The sample may then be used for Western immunoblotting and for transmission electron microscopic analysis for confirming respectively the integrity of the modified BPV1 L1 capsid protein and chimeric VLP structure.
********************** The present invention has been described in terms of particular embodiments found or proposed by the present inventors to comprise preferred modes for the practice of the invention. It will be appreciated by those of skill in the art that, in light of the instant disclosure, various modifications and changes can be made in the particular embodiments exemplified without departing from the scope of the invention. All such modifications and changes are intended to be included within the scope of the appended claims.
FIGURE LEGENDS
FIG. 1. A set of overlapping peptides (termed GF51-GF66) spanning the putative HPV16 E6 protein molecule. These peptides were synthesized by Fmoc chemistry. Peptides are shown using the single letter code. The numbers of the first and last amino acids of each peptide correspond to amino acid numbers of the HPV16 E6 polypeptide sequence.
FIG. 2. Overlapping pattern of the peptides of FIG. 1 relative to the amino acid sequence of HPV16 E6 protein. The first and last amino acid (single letter code) indicated for each peptide correspond to the amino acid numbering of HPV16 E6 protein.
FIGS. 3A and 3B. Mitogenicity and toxicity assays of the HPV16 E6 overlapping peptides. Each recall peptide was used at two different concentrations: 20 μg/mL (hatched bars), and 2 μg/mL (dotted bars). "NIL" represents background (no added antigen).
FIGS. 4A - 4D. LNC proliferation assays. Each recall peptide was used at two different concentrations: 20 μg/mL (hatched bars), and 2 μg/mL (dotted bars). "NIL" represents background (no added antigen). Irrelevant peptides GF55 (FIG. 4A), GF59 (FIG. 4B), GF63 (FIG. 4C) and GF51 (FIG. 4D) were used as negative controls in their respective groups.
FIGS. 5A - 5E. In vitro proliferative response of LNCs from H-2b mice immunized subcutaneously with an equimolar mixture of peptide GF56 FIG. 5A), GF57 (FIG. 5B), GF61 (FIG. 5C), GF66 (FIG. 5D) and GF51 (FIG. 5E). Recall peptide GF51 was used as a negative control. Mean proliferation with PPD positive control was 122.0541 x 103 cpm. "NIL" represents background (no added antigen).
FIGS. 6A - 6F. T-proliferative response of LNCs from C57BL/6 and B10 mice immunized with an equimolar mixture of peptides GF56, GF57, and GF61 in CFA, and challenged in vitro with individual peptides Each recall peptide was used at two different concentrations: 20 μg/mL (hatched bars), and 2 μg/mL (dotted bars). "NIL" represents background (no added antigen). Recall peptide GF51 was used as a negative control.
FIG. 7. Mapping of the minimal T-cell proliferative epitope in the GF57 peptide of HPV16E6 protein. Underlined amino acids indicate the minimal T-cell proliferative epitope.
FIGS. 8A and 8B. In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF57, and challenged with GF57 overlapping truncated peptides. Recall peptides GF57 and GF51 were used as positive and negative controls respectively. "NIL" represents background (no added antigen).
FIG. 9. Mapping of the minimal T-cell proliferative epitope in the GF61 peptide of HPV16E6 protein. Underlined amino acids indicate the minimal T-cell proliferative epitope.
FIGS. 10A and 10B. In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF61 , and challenged with GF57 overlapping truncated peptides. Recall peptides GF61 and GF51 were used as positive and negative controls respectively. "NIL" represents background (no added antigen).
FIGS. 11A and 11B. In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with GF57 overlapping truncated peptides. "NIL" represents background (no added antigen).
FIGS. 12A and 12B. In vitro proliferative response of LNCs from C57BL/6 mice immunized subcutaneously with peptide GF51 , and challenged with GF61 overlapping truncated peptides. "NIL" represents background (no added antigen).
FIGS. 13A - 13D. Effect of 'VYRDGNPYA' and 'QYNKPLCDLL' Th-epitopes on the antibody response to 'EYMLD' and 'QAEPD' B-epitopes. Peptide GF101 (MHGDTPTLHEYMLDLQPE) and 8Q (QAEPDRAHYNIVTFCCKCD) are HPV16 E7 peptides which contain the E7 B-epitopes EYMLD and QAEPD respectively. Used as positive controls, 8F and 6D are MAbs to EYMLD and QAEPD respectively. Sera were collected from H-2b mice before and after immunization with either VYRDGNPYA (VYR) alone, QYNKPLCDLL (QYN) alone, VYRDGNPYA linked to EYMLD and QAEPD (E-VYR-Q), QYNKPLCDLL linked to EYMLD and QAEPD (E-QYN-Q) or with a peptide consisting of EYMLD and QAEPD epitopes only (E-Q).
FIG. 14. Construction of recombinant baculovirus transfer vector pVLBPV1 L1/Thprom-QAEPD. A hybrid nucleotide sequence encoding a modified BPV1 L1 gene in which a chimeric peptide comprising VYRDGNPYA and the B-cell epitope QAEPD, is fused to the C-terminus of the BPV1 L1 sequence by PCR amplification. This fusion results in deletion of nucleotides from 7625 downstream of the BPV1 wild-type nucleotide sequence.
Claims
1. A peptide comprising the sequence of amino acids VYRDGNPYA (SEQ ID NO 1 ) inclusive of a single amino acid deletion, substitution or addition made therein.
2. A peptide homolog of the peptide according to claim 1.
3. A peptide of 10 to 34 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the sequence of amino acids defined by the peptide of claim 1 or claim 2.
4. A peptide of 13 to 20 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the sequence of amino acids defined by the peptide of claim 1 or claim 2.
5. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
6. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein said construct comprises between 10 and 34 amino acids.
7. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope wherein, said construct comprises between 13 and 20 amino acids.
8. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is from a pathogenic organism.
9. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is from a papillomavirus.
10. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is from HPV16 E7.
11. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is QAEPD or EYMLD.
12. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each CTL epitope is from a tumor or viral source.
13. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each CTL epitope is from a papillomavirus.
14. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each CTL epitope is from HPV16 E6 or HPV16 E7.
15. An immunogenic composition comprising a peptide according to claim 1 or claim 2 in combination with an adjuvant and/or a delivery vehicle.
16. An immunogenic composition comprising a peptide according to claim 1 or claim 2 in combination with an adjuvant and/or a delivery vehicle, wherein said delivery vehicle comprises a chimeric VLP including a modified viral capsid protein having said peptide fused thereto.
17. An immunogenic composition comprising a peptide according to claim 1 or claim 2 in combination with an adjuvant and/or a delivery vehicle, wherein said delivery vehicle comprises a chimeric VLP including a modified papillomavirus capsid protein having said peptide fused thereto.
18. An immunogenic composition comprising a chimeric peptide construct in combination with an adjuvant and/or a delivery vehicle, said chimeric peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
19. An immunogenic composition comprising a chimeric peptide construct in combination with an adjuvant and/or a delivery vehicle, said chimeric peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein said delivery vehicle comprises a chimeric VLP including a modified viral capsid protein having said chimeric peptide construct fused thereto.
20. An immunogenic composition comprising a chimeric peptide construct in combination with an adjuvant and/or a delivery vehicle, said chimeric peptide construct comprising a peptide according to claim 1 or claim 2 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein said delivery vehicle comprises a chimeric VLP including a modified papillomavirus capsid protein having said chimeric peptide construct fused thereto.
21. A peptide comprising the sequence of amino acids QYNKPLCDLL (SEQ ID NO 2) inclusive of a single amino acid deletion, substitution or addition made therein.
22. A peptide homolog of the peptide according to claim 21.
23. A peptide of 10 to 34 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the sequence of amino acids defined by the peptide of claim 21 or claim 22.
24. A peptide of 13 to 20 amino acids corresponding to a natural sequence of amino acids encoded by HPV16 E6 or homologous sequence thereof which natural or homologous sequence comprises the sequence of amino acids defined by the peptide of claim 21 or claim 22.
25. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
26. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein said construct comprises between 10 and 34 amino acids.
27. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope wherein, said construct comprises between 13 and 20 amino acids.
28. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is from a pathogenic organism.
29. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is from a papillomavirus.
30. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is from HPV16 E7.
31. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each B-cell epitope is QAEPD or EYMLD.
32. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each CTL epitope is from a tumor or viral source.
33. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each CTL epitope is from a papillomavirus.
34. A chimeric peptide construct for generating an immune response against one or more B-cell epitopes and/or one or more CTL epitopes said peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein the or each CTL epitope is from HPV16 E6 or HPV16 E7.
35. An immunogenic composition comprising a peptide according to claim 21 or claim 22 in combination with an adjuvant and/or a delivery vehicle.
36. An immunogenic composition comprising a peptide according to claim 21 or claim 22 in combination with an adjuvant and/or a delivery vehicle, wherein said delivery vehicle comprises a chimeric VLP including a modified viral capsid protein having said peptide fused thereto.
37. An immunogenic composition comprising a peptide according to claim 21 or claim 22 in combination with an adjuvant and/or a delivery vehicle, wherein said delivery vehicle comprises a chimeric VLP including a modified papillomavirus capsid protein having said peptide fused thereto.
38. An immunogenic composition comprising a chimeric peptide construct in combination with an adjuvant and/or a delivery vehicle, said chimeric peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope.
39. An immunogenic composition comprising a chimeric peptide construct in combination with an adjuvant and/or a delivery vehicle, said chimeric peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein said delivery vehicle comprises a chimeric VLP including a modified viral capsid protein having said chimeric peptide construct fused thereto.
40. An immunogenic composition comprising a chimeric peptide construct in combination with an adjuvant and/or a delivery vehicle, said chimeric peptide construct comprising a peptide according to claim 21 or claim 22 linked directly or indirectly to one or more amino acid sequences encoding the or each B-cell epitope and/or one or more amino acid sequences encoding the or each CTL epitope, wherein said delivery vehicle comprises a chimeric VLP including a modified papillomavirus capsid protein having said chimeric peptide construct fused thereto.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU51112/98A AU5111298A (en) | 1996-11-29 | 1997-12-01 | Novel promiscuous t helper cell epitopes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO3903 | 1996-11-29 | ||
AUPO3903A AUPO390396A0 (en) | 1996-11-29 | 1996-11-29 | Novel promiscuous T helper cell epitopes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998023635A1 true WO1998023635A1 (en) | 1998-06-04 |
Family
ID=3798212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1997/000820 WO1998023635A1 (en) | 1996-11-29 | 1997-12-01 | Novel promiscuous t helper cell epitopes |
Country Status (2)
Country | Link |
---|---|
AU (1) | AUPO390396A0 (en) |
WO (1) | WO1998023635A1 (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2794371A1 (en) * | 1999-10-07 | 2000-12-08 | Biovector Therapeutics | New polyepitopic fragments from human papilloma virus E6 and E7 proteins, useful for treatment or prevention of e.g. cervical neoplasia and cancer |
WO2000075336A3 (en) * | 1999-06-03 | 2001-07-26 | Biovector Therapeutics | Polyepitopic proteinic fragments of e6 and e7 hpv proteins, production and use thereof in vaccines |
JP2002526419A (en) * | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | Novel methods for therapeutic vaccination |
EP1292328A1 (en) * | 2000-06-21 | 2003-03-19 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
JP2003516419A (en) * | 1999-12-08 | 2003-05-13 | マインドセット・バイオファーマシューティカルズ・(ユーエスエイ)・インコーポレイテッド | Chimeric peptide as immunogen, antibody thereto, and immunization using chimeric peptide or antibody |
WO2004041067A2 (en) | 2002-11-01 | 2004-05-21 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic disease |
US6746669B1 (en) | 1999-04-23 | 2004-06-08 | Pharmexa A/S | Method for down-regulating IL5 activity |
WO2004069182A2 (en) | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
EP1502602A2 (en) * | 1998-10-05 | 2005-02-02 | Pharmexa A/S | Methods for therapeutic vaccination |
WO2006020581A2 (en) | 2004-08-09 | 2006-02-23 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US7056512B1 (en) | 1999-07-20 | 2006-06-06 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
WO2006059529A1 (en) * | 2004-11-30 | 2006-06-08 | Kurume University | Hla-a24-restricted tumor antigen peptide |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
US7135181B2 (en) | 2000-02-21 | 2006-11-14 | Pharmexa A/S | Method for down-regulation of amyloid |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
EP1947174A1 (en) * | 2000-06-21 | 2008-07-23 | MedImmune, LLC | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
WO2008131298A2 (en) | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prevention and treatment of cerebral amyloid angiopathy |
WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
US7931896B2 (en) | 2006-12-27 | 2011-04-26 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US8039589B1 (en) | 2002-10-04 | 2011-10-18 | Mayo Foundation For Medical Education And Research | B7-DC variants |
US8053414B2 (en) | 2000-04-28 | 2011-11-08 | The Johns Hopkins University | Methods of using B7-DC molecules to induce or enhance an immune response |
EP2450056A1 (en) | 2005-07-19 | 2012-05-09 | Elan Pharma International Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2583978A2 (en) | 2007-02-23 | 2013-04-24 | The Regents of the University of California | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
EP2596801A1 (en) | 2006-10-06 | 2013-05-29 | BN Immunotherapeutics, Inc. | Methods for treating cancer with mva |
US8460927B2 (en) | 1999-11-30 | 2013-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 antibodies and method of use |
WO2014062778A1 (en) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
US8747833B2 (en) | 2004-10-06 | 2014-06-10 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
US8858951B2 (en) | 2001-04-18 | 2014-10-14 | The University Of Queensland | Compositions for eliciting an immune response |
US8871212B2 (en) | 2001-08-20 | 2014-10-28 | H. Lundbeck A/S | Amyloid-beta polypeptide vaccine |
US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
WO2015175340A1 (en) | 2014-05-13 | 2015-11-19 | Bavarian Nordic, Inc. | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
EP2952524A1 (en) | 2007-10-17 | 2015-12-09 | Janssen Sciences Ireland UC | Immunotherapy regimes dependent on apoe status |
EP3067066A1 (en) | 2007-02-23 | 2016-09-14 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2017191561A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2018229156A1 (en) | 2017-06-14 | 2018-12-20 | Virometix Ag | Cyclic peptides for protection against respiratory syncytial virus |
US10167336B2 (en) | 2013-03-14 | 2019-01-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
WO2020070303A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
WO2020104531A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
WO2020127728A1 (en) | 2018-12-20 | 2020-06-25 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
WO2021099586A1 (en) | 2019-11-20 | 2021-05-27 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
WO2021260176A1 (en) | 2020-06-25 | 2021-12-30 | Virometix Ag | Synthetic epitopes of betacoronaviruses |
WO2022063990A1 (en) | 2020-09-28 | 2022-03-31 | Dbv Technologies | Particle comprising an rsv-f protein for use in rsv vaccination |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
US11926659B2 (en) | 2019-03-03 | 2024-03-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
US11958896B2 (en) | 2018-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018294A1 (en) * | 1990-05-11 | 1991-11-28 | Medscand Ab | Synthetic peptides of human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunossay for diagnostic purposes |
-
1996
- 1996-11-29 AU AUPO3903A patent/AUPO390396A0/en not_active Abandoned
-
1997
- 1997-12-01 WO PCT/AU1997/000820 patent/WO1998023635A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991018294A1 (en) * | 1990-05-11 | 1991-11-28 | Medscand Ab | Synthetic peptides of human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunossay for diagnostic purposes |
Non-Patent Citations (5)
Cited By (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820633B2 (en) | 1998-10-05 | 2010-10-26 | Bn Immunotherapeutics, Inc. | Methods for therapeutic vaccination |
EP1502602A2 (en) * | 1998-10-05 | 2005-02-02 | Pharmexa A/S | Methods for therapeutic vaccination |
EP1502602A3 (en) * | 1998-10-05 | 2006-05-17 | Pharmexa A/S | Methods for therapeutic vaccination |
US7005498B1 (en) | 1998-10-05 | 2006-02-28 | Pharmexa A/S | Methods for therapeutic vaccination |
US7807441B2 (en) | 1998-10-05 | 2010-10-05 | Bn Immunotherapeutics, Inc. | Methods for therapeutic vaccination |
JP2002526419A (en) * | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | Novel methods for therapeutic vaccination |
US6746669B1 (en) | 1999-04-23 | 2004-06-08 | Pharmexa A/S | Method for down-regulating IL5 activity |
US7285273B1 (en) | 1999-04-23 | 2007-10-23 | Pharmexa A/S | Method for down-regulating IL5 activity |
WO2000075336A3 (en) * | 1999-06-03 | 2001-07-26 | Biovector Therapeutics | Polyepitopic proteinic fragments of e6 and e7 hpv proteins, production and use thereof in vaccines |
US6783763B1 (en) | 1999-06-03 | 2004-08-31 | Peptide Immune Ligands | Polyepitopic proteinic fragments of the E6 and E7 HPV proteins, production and use thereof in vaccines |
US7288258B2 (en) | 1999-06-03 | 2007-10-30 | Peptide Immune Ligands | Polyepitopic protein fragments of the E6 and E7 proteins of HPV, their production and their use particularly in vaccination |
EP2267132A3 (en) * | 1999-06-03 | 2011-04-20 | Assistance Publique-Hopitaux | Proteinfragmente die verschiedene epitope der hpv proteine e6 und e7 umfassen, ihre herstellung und verwendungen insbesondere zur impfung |
US7070784B1 (en) | 1999-07-20 | 2006-07-04 | Pharmexa A/S | Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues |
US7056512B1 (en) | 1999-07-20 | 2006-06-06 | Pharmexa A/S | Method for down-regulating GDF-8 activity |
FR2794371A1 (en) * | 1999-10-07 | 2000-12-08 | Biovector Therapeutics | New polyepitopic fragments from human papilloma virus E6 and E7 proteins, useful for treatment or prevention of e.g. cervical neoplasia and cancer |
US8460927B2 (en) | 1999-11-30 | 2013-06-11 | Mayo Foundation For Medical Education And Research | B7-H1 antibodies and method of use |
JP2003516419A (en) * | 1999-12-08 | 2003-05-13 | マインドセット・バイオファーマシューティカルズ・(ユーエスエイ)・インコーポレイテッド | Chimeric peptide as immunogen, antibody thereto, and immunization using chimeric peptide or antibody |
US7901689B2 (en) * | 1999-12-08 | 2011-03-08 | Intellect Neurosciences, Inc. | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
US20110280879A1 (en) * | 1999-12-08 | 2011-11-17 | Intellect Neurosciences, Inc. | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
JP4804690B2 (en) * | 1999-12-08 | 2011-11-02 | インテレクト・ニューロサイエンシズ・インコーポレーテッド | Chimeric peptide as immunogen, antibody thereto, and immunization using chimeric peptide or antibody |
US7135181B2 (en) | 2000-02-21 | 2006-11-14 | Pharmexa A/S | Method for down-regulation of amyloid |
US8053558B2 (en) | 2000-04-28 | 2011-11-08 | The Johns Hopkins University | Dendritic cell co-stimulatory molecules |
US8053414B2 (en) | 2000-04-28 | 2011-11-08 | The Johns Hopkins University | Methods of using B7-DC molecules to induce or enhance an immune response |
US9370565B2 (en) | 2000-04-28 | 2016-06-21 | The Johns Hopkins University | Dendritic cell co-stimulatory molecules |
EP1292328A1 (en) * | 2000-06-21 | 2003-03-19 | Medimmune, Inc. | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
EP1947174A1 (en) * | 2000-06-21 | 2008-07-23 | MedImmune, LLC | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor |
EP1292328A4 (en) * | 2000-06-21 | 2005-01-26 | Medimmune Inc | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
US9993542B2 (en) | 2001-04-18 | 2018-06-12 | Admedus Vaccines Pty Ltd. | Compositions and uses therefor |
US8858951B2 (en) | 2001-04-18 | 2014-10-14 | The University Of Queensland | Compositions for eliciting an immune response |
US8871212B2 (en) | 2001-08-20 | 2014-10-28 | H. Lundbeck A/S | Amyloid-beta polypeptide vaccine |
EP3299029A1 (en) | 2001-08-20 | 2018-03-28 | H. Lundbeck A/S | Novel method for down-regulation of amyloid |
US8039589B1 (en) | 2002-10-04 | 2011-10-18 | Mayo Foundation For Medical Education And Research | B7-DC variants |
WO2004041067A2 (en) | 2002-11-01 | 2004-05-21 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic disease |
EP2361629A1 (en) | 2002-11-01 | 2011-08-31 | Elan Pharmaceuticals Inc. | Prevention and treatment of synucleinopathic disease |
WO2004069182A2 (en) | 2003-02-01 | 2004-08-19 | Neuralab Limited | Active immunization to generate antibodies to soluble a-beta |
EP3369433A1 (en) | 2004-08-09 | 2018-09-05 | Janssen Alzheimer Immunotherapy | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2006020581A2 (en) | 2004-08-09 | 2006-02-23 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
US8747833B2 (en) | 2004-10-06 | 2014-06-10 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
US9803015B2 (en) | 2004-10-06 | 2017-10-31 | Mayo Foundation For Medical Education And Research | Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target |
US11939378B2 (en) | 2004-10-06 | 2024-03-26 | Mayo Foundation For Medical Education And Research | Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target |
US11242387B2 (en) | 2004-10-06 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target |
WO2006059529A1 (en) * | 2004-11-30 | 2006-06-08 | Kurume University | Hla-a24-restricted tumor antigen peptide |
EP2450056A1 (en) | 2005-07-19 | 2012-05-09 | Elan Pharma International Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2008042024A2 (en) | 2006-06-01 | 2008-04-10 | Elan Pharmaceuticals, Inc. | Neuroactive fragments of app |
EP2596801A1 (en) | 2006-10-06 | 2013-05-29 | BN Immunotherapeutics, Inc. | Methods for treating cancer with mva |
US8440185B2 (en) | 2006-12-26 | 2013-05-14 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
US9134321B2 (en) | 2006-12-27 | 2015-09-15 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US7931896B2 (en) | 2006-12-27 | 2011-04-26 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
EP2583978A2 (en) | 2007-02-23 | 2013-04-24 | The Regents of the University of California | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP3067066A1 (en) | 2007-02-23 | 2016-09-14 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
WO2008131298A2 (en) | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prevention and treatment of cerebral amyloid angiopathy |
EP2952524A1 (en) | 2007-10-17 | 2015-12-09 | Janssen Sciences Ireland UC | Immunotherapy regimes dependent on apoe status |
EP2730659A2 (en) | 2007-12-28 | 2014-05-14 | Elan Pharmaceuticals Inc. | Treatment and Prophylaxis of Amyloidosis |
US7928203B2 (en) | 2007-12-28 | 2011-04-19 | Elan Pharmaceuticals, Inc. | Chimeric, humanized, or human antibody 2A4 |
WO2009086539A2 (en) | 2007-12-28 | 2009-07-09 | Elan Pharmaceuticals, Inc. | Treatment and prophylaxis of amyloidosis |
EP3693470A1 (en) | 2007-12-28 | 2020-08-12 | Prothena Therapeutics Limited | Treatment and prophylaxis of amyloidosis |
US8268973B2 (en) | 2007-12-28 | 2012-09-18 | Onclave Therapeutics | Anti-amyloid antibodies |
US8404815B2 (en) | 2007-12-28 | 2013-03-26 | Onclave Therapeutics | Chimeric, humanized, or human antibody 2A4 |
US8791243B2 (en) | 2007-12-28 | 2014-07-29 | Onclave Therapeutics Limited | Treatment and prophylaxis of amyloidosis |
US8636981B2 (en) | 2007-12-28 | 2014-01-28 | Onclave Therapeutics | Detection of amyloid deposits using anti-amyloid antibodies |
US9011853B2 (en) | 2009-08-31 | 2015-04-21 | Amplimmune, Inc. | B7-H4 fusion proteins and methods of use thereof |
US9957312B2 (en) | 2009-08-31 | 2018-05-01 | Medimmune, Llc | B7-H4 fusion proteins and methods of use thereof |
US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
WO2014062778A1 (en) | 2012-10-19 | 2014-04-24 | Bavarian Nordic, Inc. | Methods and compositions for the treatment of cancer |
EP3689904A1 (en) | 2013-03-13 | 2020-08-05 | Prothena Biosciences Limited | Tau immunotherapy |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
US11643457B2 (en) | 2013-03-13 | 2023-05-09 | Prothena Biosciences Limited | Tau immunotherapy |
US10167336B2 (en) | 2013-03-14 | 2019-01-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
US11136393B2 (en) | 2013-10-01 | 2021-10-05 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of Bim |
WO2015075635A2 (en) | 2013-11-19 | 2015-05-28 | Prothena Biosciences Limited | Monitoring immunotherapy of lewy body disease from constipation symptoms |
WO2015175340A1 (en) | 2014-05-13 | 2015-11-19 | Bavarian Nordic, Inc. | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3 |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
US11504376B2 (en) | 2014-07-23 | 2022-11-22 | Mayo Foundation For Medical Education And Research | Targeting DNA-PKCS and B7-H1 to treat cancer |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
US11584791B2 (en) | 2016-05-02 | 2023-02-21 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191561A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2018229156A1 (en) | 2017-06-14 | 2018-12-20 | Virometix Ag | Cyclic peptides for protection against respiratory syncytial virus |
EP4295866A2 (en) | 2017-06-14 | 2023-12-27 | Virometix AG | Cyclic peptides for protection against respiratory syncytial virus |
US11958896B2 (en) | 2018-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2020070303A1 (en) | 2018-10-05 | 2020-04-09 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist |
WO2020104531A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
WO2020127728A1 (en) | 2018-12-20 | 2020-06-25 | Virometix Ag | Lipopeptide building blocks and synthetic virus-like particles |
US11926659B2 (en) | 2019-03-03 | 2024-03-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2021099586A1 (en) | 2019-11-20 | 2021-05-27 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
WO2021260176A1 (en) | 2020-06-25 | 2021-12-30 | Virometix Ag | Synthetic epitopes of betacoronaviruses |
WO2022063990A1 (en) | 2020-09-28 | 2022-03-31 | Dbv Technologies | Particle comprising an rsv-f protein for use in rsv vaccination |
WO2023118508A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
AUPO390396A0 (en) | 1996-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998023635A1 (en) | Novel promiscuous t helper cell epitopes | |
EP0768893B1 (en) | Polynucleotide vaccine for papillomavirus | |
Müller et al. | Chimeric papillomavirus-like particles | |
Peng et al. | Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway | |
Liu et al. | Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity | |
US7754430B2 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
US6342224B1 (en) | Recombinant papillomavirus vaccine and method for production and treatment | |
AU766403B2 (en) | Treatment of cervical cancer | |
Liu et al. | Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes | |
US8735561B2 (en) | Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof | |
AU2001275458A1 (en) | Chimeric human papillomavirus (HPV) L1 molecules and uses therefor | |
EP1292328A1 (en) | Chimeric human papillomavirus (hpv) l1 molecules and uses therefor | |
EP1305039B1 (en) | Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof | |
WO1992010513A1 (en) | Subunit papillomavirus vaccine and peptides for use therein | |
US20020039584A1 (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
CZ20021023A3 (en) | Vaccine | |
WO2004062584A2 (en) | Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection | |
KR20210018312A (en) | Human papillomavirus 18L1 protein mutant | |
AU660954B2 (en) | Subunit papillomavirus vaccine and peptides for use therein | |
AU717932B2 (en) | Chimeric papillomavirus-like particles | |
Reichel et al. | Protein-based nanosystems: virus-like-particles in modern vaccine development | |
CZ2000634A3 (en) | Vaccine | |
AU4447899A (en) | Chimeric papillomavirus-like particles | |
MXPA00003358A (en) | Papilloma virus capsomere vaccine formulations and methods of use | |
AU2007201791A1 (en) | Papilloma virus capsomere vaccine formulations and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |